var title_f36_51_37680="Sputum Ziehl Neelsen stain";
var content_f36_51_37680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Sputum stained by Ziehl-Neelsen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sputum, decontaminated and concentrated, and stained using the Ziehl-Neelsen method.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bernardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37680=[""].join("\n");
var outline_f36_51_37680=null;
var title_f36_51_37681="Signet ring cancer CPC Endosc";
var content_f36_51_37681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Gastric signet ring cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing diffuse gastric wall thickening with poor distention of the gastric lumen when air was insufflated, suggestive of an infiltrative process. Multiple biopsies were taken throughout the stomach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nazem Afdhal, MD and Andres Cardenas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37681=[""].join("\n");
var outline_f36_51_37681=null;
var title_f36_51_37682="Tube extrusion";
var content_f36_51_37682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Tympanostomy tube extrusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 474px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The inner flange of the tube becomes visible as it presses against the eardrum and begins to extrude as the tube tips posteriorly (Panels A and B above)*. When both flanges are clearly in view, extrusion is complete (Panel C above). A residual healing perforation remains in the eardrum.",
"    <div class=\"footnotes\">",
"     * Note: tympanosclerosis distant from the tube site (arrow).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G, Rosenfeld RM. Care of the child with tympanostomy tubes. A visual guide for the pediatrician. Pediatrics 1994; 93:924. Copyright &copy; 1994 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37682=[""].join("\n");
var outline_f36_51_37682=null;
var title_f36_51_37683="Scaphocephaly";
var content_f36_51_37683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scaphocephaly (dolichocephaly)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scaphocephaly, side view (A) and top view (B). Marked increase in head length with narrowed width resulting from premature fusion of sagittal suture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher MA. Physical diagnosis in neonatology. Philadelphia: Lippincott-Raven; 1998. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37683=[""].join("\n");
var outline_f36_51_37683=null;
var title_f36_51_37684="Acute normovolemic intraoperative hemodilution";
var content_f36_51_37684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute normovolemic intraoperative hemodilution",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37684/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37684/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37684/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37684/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37684/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37684/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/51/37684/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute normovolemic (isovolemic) hemodilution (ANH), also referred to as intraoperative hemodilution, was introduced in the early 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/1\">",
"     1",
"    </a>",
"    ]. This blood conservation technique entails the removal of blood from a patient, either immediately before or shortly after induction of anesthesia, with maintenance of isovolemia using crystalloid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colloid replacement. The amount of blood removed varies between one and three units (450 to 500 mL constitutes one unit), although larger volumes may be withdrawn safely in certain circumstances (see below).",
"   </p>",
"   <p>",
"    The blood withdrawn is anticoagulated and maintained at room temperature, in the operating room, for up to eight hours. It is reinfused into the patient as needed during, or after, the surgical procedure. ANH can be used as the sole blood conservation technique, or it can be combined with preoperative autologous donation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    ), blood salvage (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10582?source=see_link\">",
"     \"Intraoperative and postoperative blood salvage\"",
"    </a>",
"    ), or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANH should be considered for patients with good initial hematocrits who are expected to lose more than two units of blood (900 to 1000 mL) during surgery. This technique is better suited to healthy, young adults, but it has been successfully employed in small children and the elderly. Operative settings in which ANH is appropriate include vascular, orthopedic, and some general surgical procedures. In addition, some Jehovah's Witnesses will agree to ANH if the blood is maintained in a closed circuit continuous flow system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ANH is contraindicated in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac disease, since the main compensatory mechanism for the induced anemia is an increase in the cardiac output. However, the decreased blood viscosity associated with the induced anemia may have cardioprotective effects in some cardiac surgical settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired renal function, since large amounts of the infused fluids will ultimately need to be excreted.",
"     </li>",
"     <li>",
"      Baseline hemoglobin &lt;11",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Low concentrations of coagulant proteins, inadequate vascular access, and the absence of appropriate monitoring capability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amount of blood to draw",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of blood that may be drawn is derived from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;V &nbsp; = &nbsp; EBV &nbsp;x &nbsp;({Ho &nbsp;- &nbsp;Hf} &nbsp;&divide; &nbsp;Hav)",
"   </p>",
"   <p>",
"    where V is the volume of blood to be removed (liters), EBV is the estimated blood volume (liters), Ho is the initial hematocrit (percent), Hf is the desired hematocrit (percent), and Hav is the average hematocrit (average of Ho and Hf). As an example, in an 70 kg patient with an estimated blood volume of 4900 mL (rounded to 5.0 L), an initial hematocrit of 45 percent, and a desired hematocrit of 30 percent, the volume of blood to be drawn is two liters (four units):",
"   </p>",
"   <p>",
"    &nbsp;V &nbsp;= &nbsp; 5.0 &nbsp;x &nbsp;( {45 - 30} &nbsp;&divide; &nbsp;37.5) &nbsp; = &nbsp; 2.0 liters",
"   </p>",
"   <p>",
"    The actual amount blood removed will depend upon the patient's initial blood volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/5\">",
"     5",
"    </a>",
"    ], tolerance of the procedure, and the anticipated blood needs. Although there is good evidence that healthy patients, appropriately monitored, can tolerate hematocrits as low as 20 percent, very few patients actually reach this level. Most anesthesiologists aim for a preoperative hematocrit between 25 and 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link&amp;anchor=H5#H5\">",
"     \"Indications for red cell transfusion in the adult\", section on 'Optimal transfusion level'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ANH is generally initiated immediately before or after the induction of anesthesia, but before the commencement of surgery. However appealing it may seem to perform ANH a day or two prior to surgery, ANH is strictly an intraoperative procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diluents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isovolemic fluid replacement can be accomplished either with colloid or crystalloid solutions. The volume infused depends upon the solution used. Crystalloids are distributed through the extracellular (intravascular plus interstitial) volume. As a result, the volume infused must exceed the volume of blood withdrawn by a factor of at least three. In comparison, colloids are restricted to the vascular space. Thus, the volume administered should approximate the volume of blood withdrawn.",
"   </p>",
"   <p>",
"    The advantage of using crystalloid to replace the withdrawn blood is the ability to remove excess fluid by the administration of diuretics, prior to transfusion. In a typical patient,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    (0.15 to 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is given five to 15 minutes before transfusion of the patient's blood.",
"   </p>",
"   <p>",
"    Given the significant fluid shifts and acute dilutional hypoalbuminemia accompanying ANH, marked peripheral edema is not uncommon. In comparison, pulmonary edema is rare in well-controlled procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Hypoalbuminemia in other edematous disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume replacement must be simultaneous with blood withdrawal. As a result, the ideal set-up consists of two large-bore cannulae placed into a central (or large peripheral) vein or an artery, most frequently the radial artery. Blood is collected in standard blood bags containing anticoagulant. Also available are hemodilution kits that contain two blood bags, a Y-type connector set with a Luer lock adapter, and a blood recipient identification band. These kits provide a measure of convenience and, absent the phlebotomy needle, a measure of safety as well.",
"   </p>",
"   <p>",
"    Cell separators, useful in intraoperative blood salvage, add an unnecessary level of complexity and are not recommended. A scale to determine the amount of blood removed is required, as is an agitator, unless gentle agitation of the blood bag during withdrawal can be accomplished by hand. An indwelling bladder catheter is also required, since the urine output serves as a guide to intravascular volume status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Handling the blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each unit of blood should be labeled with the patient's name, hospital number, time of withdrawal, and sequential number (if more than one unit is removed). According to the AABB Standards, units collected by ANH can be stored at room temperature (in the operating room) for up to eight hours; if not used within that time, they can be stored at 1 to 6&ordm; C for up to 24 hours, provided that cold storage is begun within eight hours of initiating the collection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/6\">",
"     6",
"    </a>",
"    ]. Blood removed from the operating room must contain the statement \"For autologous use only\" on the label.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The collected blood is transfused after major blood loss has ceased, or sooner if indicated. Estimation of blood loss and serial hematocrit determinations serve as a useful guide to transfusion requirements. The units are usually returned to the patient in the reverse order of collection. Thus, the first unit, which has the highest hematocrit and contains the most platelets and undiluted coagulation factors, is administered last. If, however, it is anticipated that all of the units might not be returned, the patient becomes hypervolemic in response to colloid administration, or there is an inadequate response to diuretics, it is prudent to change the sequence so that the first unit(s) do not become outdated.",
"   </p>",
"   <p>",
"    The lowest safe hematocrit level varies from individual to individual. Except for special cases of extreme hemodilution, most anesthesiologists recommend beginning blood transfusion at a hematocrit of approximately 25 percent in order to have a degree of protection if excessive bleeding should occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POTENTIAL BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major presumed benefit of ANH and other blood conservation techniques is a decrease in exposure to allogeneic blood, thereby minimizing or avoiding the risk of transmission of transfusion-associated infectious disease. Other consequences of exposure to allogeneic blood are also avoided, including allergic reactions, allosensitization, and perhaps immunomodulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ANH also has the following advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can be used in patients who, because of the emergency nature of the surgery or because they were ineligible to participate in a preoperative autologous blood donation (PAD) program, would otherwise not have an autologous transfusion option.",
"     </li>",
"     <li>",
"      It is cost effective, since testing, storage, and crossmatching costs are not incurred.",
"     </li>",
"     <li>",
"      It provides the only opportunity to transfuse patients with fresh, whole blood containing viable platelets and high levels of clotting factors.",
"     </li>",
"     <li>",
"      It increases tissue perfusion as hemodilution decreases blood viscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It may decrease the amount of red blood cells lost during surgery, since the blood lost has a lower hematocrit after hemodilution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POTENTIAL DRAWBACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread utilization of ANH has been prevented by concerns about the possible need for increased anesthesia personnel as well as the requisite intensive monitoring of aggressively hemodiluted patients. Concern has also been expressed about the potential for increased blood loss, resulting from dilution of coagulation factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/10\">",
"     10",
"    </a>",
"    ], although the opposite has been demonstrated in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even one of the major presumed benefits of ANH, the diminished loss of red cells, has been questioned by computer modeling. The savings in red cells was less than previously estimated when correction was made for the decreasing hematocrit in bleeding isovolemic patients and the associated need to begin transfusion at some minimal hematocrit level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon strict inclusion criteria, a meta-analysis of the English literature has concluded the following concerning ANH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The efficacy is likely to be small",
"     </li>",
"     <li>",
"      Bleeding and allogeneic blood requirements are only modestly reduced",
"     </li>",
"     <li>",
"      Efficacy with regard to avoidance of allogeneic transfusion is unproven",
"     </li>",
"     <li>",
"      Safety has not been addressed adequately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the judgments rendered by the authors of this meta-analysis are valid, more definitive studies need to be conducted prior to recommending widespread use of ANH.",
"   </p>",
"   <p>",
"    Additional comments on the benefits versus drawbacks of ANH have been in the literature for some time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A thoughtful editorial has assessed the hazards of over-interpreting mathematical modeling of blood loss, the need for (and feasibility of performing) additional randomized controlled trials, and other issues that will help bring the current status of ANH into clearer focus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37684/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23612635\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute normovolemic hemodilution (ANH) entails the removal of blood immediately before or shortly after induction of anesthesia, with maintenance of isovolemia using crystalloid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colloid. The blood is anticoagulated, maintained at room temperature in the operating room for up to eight hours, and is reinfused as needed during, or after, the surgical procedure. ANH can be used as the sole blood conservation technique, or it can be combined with preoperative autologous donation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ANH is generally indicated for patients with good initial hematocrits who are expected to lose more than two units of blood (900 to 1000 mL) during surgery. ANH is contraindicated in those with cardiac disease, impaired renal function, hemoglobin &lt;11",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      low concentrations of coagulant proteins, inadequate vascular access, and the absence of appropriate monitoring capability. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The amount of blood removed depends upon the patient's blood volume, tolerance of the procedure, and anticipated blood needs. Most anesthesiologists aim for a preoperative hematocrit between 25 and 30 percent and recommend beginning blood transfusion at a hematocrit of approximately 25. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Technical considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both the potential benefits and drawbacks of ANH have been vigorously debated. More definitive trials are needed before widespread use of ANH can be recommended. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Potential benefits'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Potential drawbacks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/1\">",
"      Messmer K. Hemodilution. Surg Clin North Am 1975; 55:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/2\">",
"      Schaller RT Jr, Schaller J, Morgan A, Furman EB. Hemodilution anesthesia: a valuable aid to major cancer surgery in children. Am J Surg 1983; 146:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/3\">",
"      Licker M, Ellenberger C, Sierra J, et al. Cardioprotective effects of acute normovolemic hemodilution in patients undergoing coronary artery bypass surgery. Chest 2005; 128:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/4\">",
"      Licker M, Sierra J, Kalangos A, et al. Cardioprotective effects of acute normovolemic hemodilution in patients with severe aortic stenosis undergoing valve replacement. Transfusion 2007; 47:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/5\">",
"      Jacob M, Bruegger D, Conzen P, et al. Development and validation of a mathematical algorithm for quantifying preoperative blood volume by means of the decrease in hematocrit resulting from acute normovolemic hemodilution. Transfusion 2005; 45:562.",
"     </a>",
"    </li>",
"    <li>",
"     AABB Standards for Blood Banks and Transfusion Services,16th ed, November 1, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/7\">",
"      Bennett J, Haynes S, Torella F, et al. Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial. Transfusion 2006; 46:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/8\">",
"      Fan FC, Chen RY, Schuessler GB, Chien S. Effects of hematocrit variations on regional hemodynamics and oxygen transport in the dog. Am J Physiol 1980; 238:H545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/9\">",
"      Stehling L, Zauder HL. Acute normovolemic hemodilution. Transfusion 1991; 31:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/10\">",
"      Rosberg B. Blood coagulation during and after normovolemic hemodilution in elective surgery. Ann Clin Res 1981; 13 Suppl 33:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/11\">",
"      Milam JD, Austin SF, Nihill MR, et al. Use of sufficient hemodilution to prevent coagulopathies following surgical correction of cyanotic heart disease. J Thorac Cardiovasc Surg 1985; 89:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/12\">",
"      Brecher ME, Rosenfeld M. Mathematical and computer modeling of acute normovolemic hemodilution. Transfusion 1994; 34:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/13\">",
"      Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion 2004; 44:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/14\">",
"      Stehling L, Zauder HL. Controversies in transfusion medicine. Perioperative hemodilution: pro. Transfusion 1994; 34:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/15\">",
"      Gillon J. Controversies in transfusion medicine. Acute normovolemic hemodilution in elective major surgery: con. Transfusion 1994; 34:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/16\">",
"      Shander A, Perelman S. The long and winding road of acute normovolemic hemodilution. Transfusion 2006; 46:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37684/abstract/17\">",
"      Jarnagin WR, Gonen M, Maithel SK, et al. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg 2008; 248:360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7936 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37684=[""].join("\n");
var outline_f36_51_37684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23612635\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amount of blood to draw",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diluents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Handling the blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POTENTIAL BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POTENTIAL DRAWBACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23612635\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10582?source=related_link\">",
"      Intraoperative and postoperative blood salvage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_51_37685="Cardiovascular risks of hypertension";
var content_f36_51_37685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiovascular risks of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37685/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/51/37685/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is quantitatively the most important risk factor for premature cardiovascular disease, being more common than cigarette smoking, dyslipidemia, and diabetes, which are the other major risk factors (",
"    <a class=\"graphic graphic_table graphicRef81993 \" href=\"mobipreview.htm?18/25/18844\">",
"     table 1",
"    </a>",
"    )&nbsp;. Hypertension accounts for an estimated 54 percent of all strokes and 47 percent of all ischemic heart disease events globally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension increases the risk for a variety of cardiovascular diseases, including stroke, coronary artery disease, heart failure, and peripheral vascular disease. Coronary disease in men and stroke in women are the principal first cardiovascular events noted after hypertension onset, as observed from data from the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/2\">",
"     2",
"    </a>",
"    ]. In view of the evidence that the mortality rates are rising in younger people in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/3\">",
"     3",
"    </a>",
"    ] and the increasing impact of cardiovascular diseases in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/4\">",
"     4",
"    </a>",
"    ], greater attention must be given to prevention of these diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for both coronary disease and stroke increases progressively with incremental increases in blood pressure above",
"    <span class=\"nowrap\">",
"     115/75",
"    </span>",
"    mmHg, as shown in numerous epidemiologic studies (",
"    <a class=\"graphic graphic_figure graphicRef75106 graphicRef66793 \" href=\"mobipreview.htm?33/12/33986\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, these observations do not prove a causal relationship, since increasing blood pressure could be a marker for other risk factors such as increasing body weight, which is associated with dyslipidemia, glucose intolerance, and the metabolic syndrome. The best evidence for a causal role of increasing blood pressure in cardiovascular complications is an improvement in outcome with antihypertensive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in cardiovascular risk has primarily been described in terms of elevated systolic pressure in those over age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/8\">",
"     8",
"    </a>",
"    ] and elevation in diastolic pressure in younger individuals. Pulse pressure, which is the difference between the systolic and diastolic blood pressures and is determined primarily by large artery stiffness, is also a strong predictor of risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypertension: Who should be treated?\", section on 'What level of BP increases risk?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Projections have been made for the expected decrease in morbidity and mortality resulting from a 10 to 12 mmHg reduction in systolic pressure and a 5 to 6 mmHg reduction in diastolic pressure using data from multiple clinical trials performed over the past 30 years. Although not proving cause-and-effect, the estimated benefit from this degree of blood pressure lowering is a 38 percent reduction in risk of stroke and a 16 percent reduction in risk of coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADDITIVE EFFECTS OF MULTIPLE RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As most vividly portrayed in the Framingham Heart Study, which has been ongoing for decades, the different coronary risk factors have an additive effect on the likelihood of developing coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In addition to hypertension, the major risk factors are older age, elevated plasma cholesterol, a low HDL-cholesterol, diabetes mellitus, cigarette smoking, and left ventricular hypertrophy (LVH) by electrocardiogram. Thus, individual patients who have significant hypertension but none or few of the other risk factors are at relatively less overall risk than are patients with less hypertension but more of the other risk factors (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Specific issues related to cardiovascular risk factors in women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The Framingham findings have been replicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], but the degree of cardiovascular risk related to the Framingham risk criteria may not apply to all patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. As an example, a prospective cohort study of over 4000 middle-aged European patients with hypertension evaluated the actual risk of coronary heart disease and stroke at a median follow-up of 3.7 years versus the predicted risk in this time period as provided by the Framingham data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/16\">",
"     16",
"    </a>",
"    ]. The actual risk of coronary disease was overestimated by the United States data in all countries, ranging from 2 percent in the United Kingdom to 7 percent in France, while the predicted and actual risks for stroke were similar.",
"   </p>",
"   <p>",
"    Other risk factors have been proposed to improve upon the Framingham risk assessment, including C-reactive protein, brain natriuretic peptide, echocardiography and other studies for detecting subclinical vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. However, none has been proven to add significantly to the Framingham scoring, and they are probably not cost-effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPLICATION OF RISK ASSESSMENT TO THERAPEUTIC DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A group from New Zealand has taken these risk factors into account in determining the overall risk status of individual patients, along with their level of blood pressure, age and gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/12\">",
"     12",
"    </a>",
"    ]. They then examined the evidence of benefits of antihypertensive therapy from the clinical trials and considered the costs of such therapy, concluding that antihypertensive therapy can be justified only if the risk for a major cardiovascular event over the next five years was 10 percent or greater, or if the level of blood pressure was so high as to mandate therapy regardless of overall risk status",
"    <span class=\"nowrap\">",
"     (&ge;170/100",
"    </span>",
"    mmHg).",
"   </p>",
"   <p>",
"    This approach requires that age, gender, and a number of cardiovascular risk factors be taken into account when considering when hypertension should be treated (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Current risk versus prior risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the specific patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/16\">",
"     16",
"    </a>",
"    ], another problem with the use of such data is that the risk status that is currently assessed may not reflect what was present previously. This is an important issue because it is the",
"    <strong>",
"     prior",
"    </strong>",
"    risk status that is more likely to be responsible for the current health of the individual.",
"   </p>",
"   <p>",
"    As an example, although blood pressure at the time of risk assessment (current blood pressure) is typically used in most prediction algorithms, this does not accurately reflect an individual's past blood pressure experience; the use of long-term average blood pressure is more accurate. This is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 3560 individuals, the presence of prehypertension before age 35 was associated with coronary calcification (which is a strong predictor of future coronary heart disease) later in life. This association was observed after adjusting for blood pressure and other coronary risk factors that were present after age 35 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from the Framingham Heart Study found that recent and remote antecedent blood pressure (systolic, diastolic, and pulse pressure) predicted cardiovascular risk incrementally over current blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/22\">",
"       22",
"      </a>",
"      ]. This effect was seen in men and women, younger and older subjects, and lower and higher blood pressure groups.",
"     </li>",
"     <li>",
"      In another study, 1604 men whose risk status was first assessed when they were aged 45 to 64 and free of clinically obvious cardiovascular disease were then reassessed 25 years later when they were aged 70 to 90 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/23\">",
"       23",
"      </a>",
"      ]. Most patients changed their risk status over this time period, moving forward or backward. When the current risk status of the 342 subjects who developed cardiovascular disease (myocardial infarction, angina, coronary bypass surgery, angioplasty, or stroke) during the follow-up period was compared with that of the 279 who remained healthy, there were few differences. However, the results were different when the original risk status was used. Those patients who remained healthy had significantly lower blood pressure",
"      <span class=\"nowrap\">",
"       (121/79",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       134/83",
"      </span>",
"      mmHg) and plasma cholesterol levels (211 versus 226",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.45 versus 5.84",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      25 years before.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors' conclusions inject some needed caution in the use of risk factor analysis when deciding to treat hypertension in older subjects: \"Since midlife values are more likely to represent lifelong exposure values that, in turn, make the main contribution to the development of atherosclerosis, investigators and clinicians may need to be cautious in using risk factor values measured late in life as the only means of assessing risk for subsequent disease\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37685/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall cardiovascular risk assessment, as well as blood pressure, should be taken into account when deciding upon proper treatment in a patient with mild hypertension. At least some of the blood pressure measurements should ideally be obtained out of the office to avoid unnecessary treatment of \"white coat\" hypertension and to facilitate recognition of \"masked hypertension.\" (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lifestyle modifications (nonpharmacologic therapy) should be recommended to all patients with blood pressures between 120 to",
"    <span class=\"nowrap\">",
"     139/80",
"    </span>",
"    to 89 mmHg (now defined as prehypertension) and also to all those with sustained hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=see_link\">",
"     \"Prehypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antihypertensive drugs should be instituted if, after several blood pressure measurements, the average blood pressure is",
"    <span class=\"nowrap\">",
"     &ge;140/90",
"    </span>",
"    mmHg. The goal blood pressure is less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in most patients. Goal blood pressure in patients with atherosclerotic cardiovascular disease, diabetes mellitus, or chronic kidney disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/1\">",
"      Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/2\">",
"      Lloyd-Jones DM, Leip EP, Larson MG, et al. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension 2005; 45:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/3\">",
"      Greenland P, Lloyd-Jones D. Time to end the mixed--and often incorrect--messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol 2007; 50:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/4\">",
"      Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007; 370:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/5\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/6\">",
"      Pastor-Barriuso R, Banegas JR, Dami&aacute;n J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/7\">",
"      Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med 2008; 149:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/8\">",
"      Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/9\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/10\">",
"      Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/11\">",
"      Kannel WB, Wolf PA. Framingham Study insights on the hazards of elevated blood pressure. JAMA 2008; 300:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/12\">",
"      Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/13\">",
"      Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/14\">",
"      Frost PH, Davis BR, Burlando AJ, et al. Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. Circulation 1996; 94:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/15\">",
"      Lowe LP, Greenland P, Ruth KJ, et al. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/16\">",
"      Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/17\">",
"      Conroy RM, Py&ouml;r&auml;l&auml; K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/18\">",
"      Simon A, Chironi G, Levenson J. Performance of subclinical arterial disease detection as a screening test for coronary heart disease. Hypertension 2006; 48:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/19\">",
"      Olsen MH, Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 2006; 24:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/20\">",
"      Cuspidi C, Meani S, Valerio C, et al. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 2006; 24:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/21\">",
"      Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/22\">",
"      Vasan RS, Massaro JM, Wilson PW, et al. Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study . Circulation 2002; 105:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37685/abstract/23\">",
"      Benfante R, Hwang LJ, Masaki K, Curb JD. To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program. Am J Epidemiol 1994; 140:206.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3850 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37685=[""].join("\n");
var outline_f36_51_37685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADDITIVE EFFECTS OF MULTIPLE RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPLICATION OF RISK ASSESSMENT TO THERAPEUTIC DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Current risk versus prior risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3850|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/61/20447\" title=\"figure 1A\">",
"      CHD mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/18/12591\" title=\"figure 1B\">",
"      Stroke mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25086\" title=\"figure 2\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/25/18844\" title=\"table 1\">",
"      Components cardiovascular risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=related_link\">",
"      Prehypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_51_37686="Stasis dermatitis petechiae";
var content_f36_51_37686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72689%7EDERM%2F80847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72689%7EDERM%2F80847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Petechiae in stasis dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous petechiae are present on the lower leg in this patient with stasis dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maculopapular drug eruption with lower extremity purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Purpuric lesions can occur in sites of nonvasculitic cutaneous inflammation. This is evident on one leg in this patient with a maculopapular drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37686=[""].join("\n");
var outline_f36_51_37686=null;
var title_f36_51_37687="ECG tutorial: Basic principles of ECG analysis";
var content_f36_51_37687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Basic principles of ECG analysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37687/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37687/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37687/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37687/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37687/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/51/37687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even though there continues to be new technologies developed for the diagnostic evaluation of patients with cardiovascular disease, the electrocardiogram (ECG) retains its central role. The ECG is the most important test for interpretation of the cardiac rhythm, conduction system abnormalities, and for the detection of myocardial ischemia. The ECG is also of great value in the evaluation of other types of cardiac abnormalities including valvular heart disease, cardiomyopathy, pericarditis, and hypertensive disease. Finally, the ECG can be used to monitor drug treatment (specifically antiarrhythmic therapy) and to detect metabolic disturbances.",
"   </p>",
"   <p>",
"    A systematic approach to interpretation of the ECG is important in order to avoid overlooking important abnormalities. Pattern recognition can be useful, but only after certain salient features have been determined. This topic review provides the framework for a systematic analysis of the ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECG GRID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG is a plot of voltage on the vertical axis against time on the horizontal axis. The electrodes are connected to a galvanometer that records a potential difference. The needle (or pen) of the ECG is deflected a given distance depending upon the voltage measured.",
"   </p>",
"   <p>",
"    The ECG waves are recorded on special graph paper that is divided into 1 mm",
"    <sup>",
"     2",
"    </sup>",
"    grid-like boxes (",
"    <a class=\"graphic graphic_figure graphicRef62799 \" href=\"mobipreview.htm?18/13/18641\">",
"     figure 1",
"    </a>",
"    ). The ECG paper speed is ordinarily 25",
"    <span class=\"nowrap\">",
"     mm/sec.",
"    </span>",
"    As a result, each 1 mm (small) horizontal box corresponds to 0.04 second (40 ms), with heavier lines forming larger boxes that include five small boxes and hence represent 0.20 sec (200 ms) intervals. On occasion, the paper speed is increased to 50",
"    <span class=\"nowrap\">",
"     mm/sec",
"    </span>",
"    to better define waveforms. In this situation there are only six leads per sheet of paper. Each large box is therefore only 0.10 sec and each small box is only 0.02 sec. In addition, the heart rate appears to be one-half of what is recorded at 25",
"    <span class=\"nowrap\">",
"     mm/sec",
"    </span>",
"    paper speed, and all of the ECG intervals are twice as long as normal.",
"   </p>",
"   <p>",
"    Vertically, the ECG graph measures the height (amplitude) of a given wave or deflection, as 10 mm (10 small boxes) equals 1 mV with standard calibration. On occasion, particularly when the waveforms are small, double standard is used (20 mm equals 1 mv). When the wave forms are very large, half standard may be used (5 mm equals 1 mv). Paper speed and voltage are usually printed on the bottom of the ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLEXES AND INTERVALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal electrocardiogram is composed of several different waveforms that represent electrical events during each cardiac cycle in various parts of the heart (",
"    <a class=\"graphic graphic_figure graphicRef67069 \" href=\"mobipreview.htm?20/56/21389\">",
"     figure 2",
"    </a>",
"    ). ECG waves are labeled alphabetically starting with the P wave, followed by the QRS complex and the ST-T-U complex (ST segment, T wave, and U wave). The J point is the junction between the end of the QRS and the beginning of the ST segment (",
"    <a class=\"graphic graphic_waveform graphicRef82922 \" href=\"mobipreview.htm?22/55/23417\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     P wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;The P wave represents atrial depolarization. The normal sinus P wave demonstrates right followed by left atrial depolarization and is an initial low amplitude positive deflection preceding the QRS complex. The duration is generally &lt;0.12 sec (three small boxes) and the amplitude &lt;0.25 mv (2.5 small boxes). Since right atrial depolarization precedes that of the left atrium (as the sinus node is in the high right atrium), the P wave is often notched in the limb leads and usually biphasic in lead V1. The initial positive deflection in V1 is due to right atrial depolarization that is directed anteriorly, while the second negative deflection represents left atrial depolarization that is directed posteriorly.",
"   </p>",
"   <p>",
"    The atrial repolarization sequence (atrial ST and T wave phases) occurs just before, simultaneously, and just after depolarization of the ventricular myocardium. The atrial \"T wave\" itself is usually hidden by the QRS complex and not observed on the routine ECG. In addition, the amplitude of the atrial T wave is often too small to be observed at standard gain. When the heart rate is increased (eg, with sinus tachycardia) and there is enhanced sympathetic tone, the PR interval is shortened; atrial repolarization (the atrial T wave) may sometimes then be observed at the very end of the QRS complex, altering the J point, and resulting in J point depression with rapidly upsloping ST segments, particularly during the first 80 msec after the QRS complex. This finding is physiologic but may be confused with true ST depression, generating a false positive reading. Clinically, atrial repolarization (the atrial ST phase) is most evident during acute pericarditis, in which one often sees PR segment elevation in lead aVR and PR segment in infero-lateral leads, reflecting an atrial current of injury. The low amplitude atrial T wave may also be unmasked in certain cases of high degree AV block, especially when the atria are enlarged. Finally, alterations in the atrial ST segment and T wave may occur with other pathologies, such as atrial infarction or atrial tumor invasion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PR interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PR interval includes the P wave as well as the PR segment. It is measured from the beginning of the P wave to the first part of the QRS complex (which may be a Q wave or R wave). It includes time for atrial depolarization (the P wave) and conduction through the AV node and the His-Purkinje system (which constitute the PR segment). The length of the PR interval changes with heart rate, but is normally 0.12 to 0.20 sec (three to five small boxes). The PR interval is shorter at faster heart rates due to sympathetically mediated enhancement of AV nodal conduction; it is longer when the rate is slowed as a consequence of slower AV nodal conduction resulting from withdrawal of sympathetic tone or an increase in vagal inputs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     QRS complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QRS complex represents the time for ventricular depolarization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial deflection is negative, it is termed a Q wave. Small Q waves are often seen in leads I, aVL, and V4-V6 as a result of initial septal depolarization and are considered normal.",
"     </li>",
"     <li>",
"      The first positive deflection of the QRS complex is called the R wave. It represents depolarization of the left ventricular myocardium. Right ventricular depolarization is obscured because the left ventricular myocardial mass is much greater than that of the right ventricle. The small R wave in lead V1 represents initial septal depolarization.",
"     </li>",
"     <li>",
"      The negative deflection following the R wave is the S wave, which represents terminal depolarization of the high lateral wall.",
"     </li>",
"     <li>",
"      If there is a second positive deflection it is known as an R'.",
"     </li>",
"     <li>",
"      Lower case letters (q, r, or s) are used for relatively small amplitude waves of less than 0.5 mV (less than 5 mm with standard calibration).",
"     </li>",
"     <li>",
"      An entirely negative QRS complex is called a QS wave.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The entire QRS duration normally lasts for 0.06 to 0.10 seconds (1&frac12; to 2&frac12; small boxes) and is not influenced by heart rate.",
"   </p>",
"   <p>",
"    The R wave should progress in size across the precordial leads V1-V6. Normally there is a small R wave in lead V1 with a deep S wave. The R wave amplitude should increase in size until V4-V6, due to more left ventricular forces being seen, while the S wave becomes less deep. This is termed R wave progression across the precordium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ST segment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ST segment occurs after ventricular depolarization has ended and before repolarization has begun. It is a time of electrocardiographic silence. The initial part of the ST segment (the intersection of the end of the QRS complex and the beginning of the ST segment) is termed the J point (",
"    <a class=\"graphic graphic_waveform graphicRef82922 \" href=\"mobipreview.htm?22/55/23417\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ST segment is usually isoelectric (ie, zero potential as identified by the T-P segment) and has a slight upward concavity. However, it may have other configurations depending upon associated disease states (eg, ischemia, acute myocardial infarction, or pericarditis). In these situations, the ST segment may be flattened, depressed (below the isoelectric line) with an upsloping, horizontal, or downsloping morphology, or elevated in a concave or convex direction (above the isoelectric line). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In some normal cases (as with sinus tachycardia) the J point is depressed and the ST segment is rapidly upsloping, becoming isoelectric within 0.08 seconds after the end of the QRS complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     T wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T wave represents the period of ventricular repolarization. Since the rate of repolarization is slower than depolarization, the T wave is broad, has a slow upstroke, and rapidly returns to the isoelectric line following its peak (ie, slow upstroke, rapid downstroke). Thus, the T wave is asymmetric and the amplitude is variable. In addition, the T wave is usually smooth up and down. If there is any irregularity on the T wave (bump, notch, rippled, nipple, etc) a superimposed P wave should be considered.",
"   </p>",
"   <p>",
"    Since depolarization begins at the endocardial surface and spreads to the epicardium, while repolarization begins at the epicardial surface and spreads to the endocardium, the direction of ventricular depolarization is opposite to that of ventricular repolarization. Thus, the T wave vector on the ECG normally is in the same direction as the major deflection of the QRS. Another way of saying this is that the QRS and T wave axes are generally concordant. Various disease states can lead to T wave discordance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QT interval consists of the QRS complex, the ST segment, and T wave. Thus, the QT interval is primarily a measure of ventricular repolarization. The JT interval, which does not include the QRS complex, is a more accurate measure of ventricular repolarization since it does not include ventricular depolarization, but in most clinical situations, the QT interval is used. If the QRS complex duration is increased, this will lead to an increase in QT interval but does not reflect a change in ventricular repolarization. A widened QRS, therefore, must be considered if a prolonged QT interval is being evaluated.",
"   </p>",
"   <p>",
"    The time for ventricular repolarization and therefore the QT (or JT) interval is dependent upon the heart rate; it is shorter at faster heart rates and longer when the rate is slower. Thus, a QT interval that is corrected for heart rate (QTc) is often calculated as follows (based on Bazett's formula):",
"   </p>",
"   <p>",
"    &nbsp;QTc &nbsp; = &nbsp; QT interval &nbsp;&divide; &nbsp;square root of the RR interval (in sec)",
"   </p>",
"   <p>",
"    Although this approach is simple, it is inaccurate at heart rate extremes and results in overcorrecting at high rates and under correcting at low ones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach corrects the QT interval to the cubed root of the RR interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Linear and logarithmic regression formulas have been used to predict the effect of heart rate on QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, because of substantial variability of the QT-RR relationship among individuals, no formula for heart rate correction can be accurate for everyone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal value for the QTc in men is &le;0.44 sec and in women is &le;0.45 to 0.46 sec. QTc values, however, are on a bell curve and normal patients may have longer QTc values, while those with Long QT syndrome may have shorter QT values. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33897?source=see_link\">",
"     \"Diagnosis of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the QRS widens in the setting of a bundle branch block, the QT interval will widen. This increase in QT interval does not reflect an abnormality of ventricular repolarization, since the increase is due to an abnormality of depolarization. There have not been many descriptions on how to measure QT interval in the setting of QRS widening. One option is to measure the JT interval, corrected for rate: QTc &ndash; QRS = JTc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/7\">",
"     7",
"    </a>",
"    ]. This equation has some limitations, as it is dependent on heart rate and as normal values haven&rsquo;t been derived.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     U wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;A U wave may be seen in some leads, especially the precordial leads V2 to V4. The exact cause of this wave is uncertain, although it has been suggested that it represents repolarization of the His-Purkinje system. Alternatively, more recent data suggest it may be due to late repolarization of the mid-myocardial M cells, due to a longer action potential duration compared to the endocardium or epicardium, especially at slow heart rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amplitude of the U wave is typically less than 0.2 mV and is clearly separate from the T wave. It is more evident in some circumstances such as hypokalemia and bradycardia. The U wave may merge with the T wave when the QT interval is prolonged (a QT-U wave), or may become very obvious when the QT or JT interval is shortened (eg, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or hypercalcemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEART RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the cardiac rhythm is regular, the interval between successive QRS complexes determined from the ECG grid can be used to determine heart rate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The division of 300 by the number of large boxes calculates the heart rate. If the interval between two successive complexes is one large box, then the rate is 300",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      (300 &divide; 1 = 300",
"      <span class=\"nowrap\">",
"       beats/min).",
"      </span>",
"      If the interval is two large boxes, the rate is 150 (300 &divide; 2 = 150",
"      <span class=\"nowrap\">",
"       beats/min).",
"      </span>",
"      This calculation may be carried on down the line for each additional large box, to 100",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      75",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      60",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      50",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      etc.",
"     </li>",
"     <li>",
"      Alternatively, the time between QRS complexes can be measured in seconds. This number can be divided into 60 to derive the heart rate. For instance, if the time between two QRS complexes is 0.75 seconds, the heart rate is 80",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      (60",
"      <span class=\"nowrap\">",
"       seconds/minute",
"      </span>",
"      &divide; 0.75",
"      <span class=\"nowrap\">",
"       seconds/beat",
"      </span>",
"      = 80",
"      <span class=\"nowrap\">",
"       beats/min).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the rhythm is irregular, the simplest way to determine the rate is by counting the number of complexes on the ECG and multiplying by six, since the standard ECG displays 10 seconds of time.",
"   </p>",
"   <p>",
"    A rate of 60 to 100 is considered normal. A rate less than 60 is bradycardia, while a rate over 100 is tachycardia (",
"    <a class=\"graphic graphic_algorithm graphicRef85685 graphicRef85684 \" href=\"mobipreview.htm?39/38/40544\">",
"     algorithm 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     AXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrical signal recorded on the ECG contains information relative to direction and magnitude of the various complexes. The average direction of any of the complexes can be determined.",
"   </p>",
"   <p>",
"    The normal QRS electrical axis, as established in the frontal plane, is between -30 and 90&ordm; (directed downward or inferior and to the left) in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37687/abstract/9\">",
"     9",
"    </a>",
"    ]. An axis between -30&ordm; and -90&ordm; (directed superior and to the left) is termed left axis deviation. If the axis between 90&ordm; and 180&ordm; (directed inferior and to the right), then right axis deviation is present. An axis between -90&ordm; and -180&ordm; (directed superior and to the right) is referred to as extreme right or left axis. If the QRS is equiphasic in all leads with no dominant QRS deflection, it is indeterminate axis. The QRS axis moves leftward throughout childhood and adolescence, from a normal value of 30 to 190&ordm; at birth to 0 to 120&ordm; during ages 8 to 16 years. There is some disagreement among authors on the definitions (in degrees) of a normal, right, and left axis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16886?source=see_link\">",
"     \"Left anterior fascicular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16420?source=see_link\">",
"     \"Left posterior fascicular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The QRS axis can be determined by examining all of the limb leads, but the easiest method involves looking only at leads I and II only (",
"    <a class=\"graphic graphic_figure graphicRef85682 \" href=\"mobipreview.htm?40/54/41838\">",
"     figure 3",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the QRS complex is positive (upright) in both leads I and II, then the axis falls between -30 and 90&ordm;, and the axis is normal.",
"     </li>",
"     <li>",
"      If the QRS complex is positive in lead I but negative in lead II, then the axis is leftward (-30 to -90&ordm;).",
"     </li>",
"     <li>",
"      If the complexes are negative in lead I and positive in aVF, then the axis is rightward (90 to 180&ordm;).",
"     </li>",
"     <li>",
"      If the complexes are negative in both I and II, then the axis is extreme (180 to -90&ordm;).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another method of axis determination is to find the lead in which the complex is most isoelectric; the axis is directed perpendicular to this lead. As an example, if the QRS is isoelectric in lead 3 which is directed at 120&ordm;, then the electrical axis is either 30&ordm; or -150&ordm;.",
"   </p>",
"   <p>",
"    A third method is to determine the frontal lead in which the QRS is of the greatest positive amplitude. The axis is parallel to this lead.",
"   </p>",
"   <p>",
"    By combining the quadrant determined by analysis of leads I and II with the isoelectric lead information, one can accurately and rapidly determine the electrical axis.",
"   </p>",
"   <p>",
"    The causes of right axis deviation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal variation (vertical heart with an axis of 90&ordm;)",
"     </li>",
"     <li>",
"      Mechanical shifts, such as inspiration and emphysema",
"     </li>",
"     <li>",
"      Right ventricular hypertrophy",
"     </li>",
"     <li>",
"      Right bundle branch block",
"     </li>",
"     <li>",
"      Left posterior fascicular block",
"     </li>",
"     <li>",
"      Dextrocardia",
"     </li>",
"     <li>",
"      Ventricular ectopic rhythms",
"     </li>",
"     <li>",
"      Pre-excitation syndrome (Wolff-Parkinson-White)",
"     </li>",
"     <li>",
"      Lateral wall myocardial infarction",
"     </li>",
"     <li>",
"      Secundum atrial septal defect",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes for left axis deviation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal variation (physiologic, often with age)",
"     </li>",
"     <li>",
"      Mechanical shifts, such as expiration, high diaphragm (pregnancy, ascites, abdominal tumor)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy",
"     </li>",
"     <li>",
"      Left bundle branch block",
"     </li>",
"     <li>",
"      Left anterior fascicular block",
"     </li>",
"     <li>",
"      Congenital heart disease (primum atrial septal defect, endocardial cushion defect)",
"     </li>",
"     <li>",
"      Emphysema",
"     </li>",
"     <li>",
"      Hyperkalemia",
"     </li>",
"     <li>",
"      Ventricular ectopic rhythms",
"     </li>",
"     <li>",
"      Pre-excitation syndromes (Wolff-Parkinson-White)",
"     </li>",
"     <li>",
"      Inferior wall myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The heart also has an axis in the horizontal plane, which is determined by imagining the heart as viewed from under the diaphragm. If the axis is rotated in a clockwise direction, left ventricular forces are directed more posteriorly and occur later in the precordial leads. This is termed poor R wave progression and late transition. If there is counterclockwise rotation, left ventricular forces occur earlier in the right precordial leads and this is termed early transition in which there is a tall R wave in lead V2.",
"   </p>",
"   <p>",
"    There is no agreement on how to estimate the QRS axis in patients with bundle branch block (BBB). As the prolonged terminal part of the QRS in right BBB reflects delays in right ventricular activation, and axis determination is of importance in&nbsp;diagnosing fascicular blocks,&nbsp;one reasonable approach is to estimate the frontal plane QRS axis based on just the first 80 to 100 ms of the QRS deflection&nbsp;(primarily reflecting activation of the left ventricle). For left BBB and other intraventricular conduction delays, the entire QRS can be used or just the initial 80 to 100 ms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491801\">",
"    <span class=\"h1\">",
"     APPROACH TO ECG INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach to interpreting an ECG is essential for correct diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491826\">",
"    <span class=\"h2\">",
"     Step 1: Rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Is the rate between 60 and 100? Rates less than 60 are bradycardic and greater than 100 are tachycardic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491838\">",
"    <span class=\"h2\">",
"     Step 2: Rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Are P waves present? Is there a P wave before every QRS complex and a QRS complex after every P wave? Are the P waves and QRS complexes regular? Is the PR interval constant? (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Rhythm analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491872\">",
"    <span class=\"h2\">",
"     Step 3: Axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Is there left or right axis deviation? (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Axis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491898\">",
"    <span class=\"h2\">",
"     Step 4: Intervals",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the PR interval? Short PR intervals are suggestive of Wolff-Parkinson-White syndrome. Long PR intervals are usually seen in first degree AV block, but there may be other causes. What is the QRS interval? Long QRS intervals represent a bundle branch block, ventricular preexcitation, ventricular pacing, or ventricular tachycardia. What is the QT interval? Short and long QT intervals may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491935\">",
"    <span class=\"h2\">",
"     Step 5: P wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the shape and axis of the P wave? The P wave morphology should be examined to determine if the rhythm is sinus or from another atrial location. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'P wave'",
"    </a>",
"    above.) Amplitude and duration should also be analyzed to determine left and right atrial enlargement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2086?source=see_link\">",
"     \"Normal sinus rhythm and sinus arrhythmia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491985\">",
"    <span class=\"h2\">",
"     Step 6: QRScomplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Is the QRS wide? If so, examination of the morphology can determine if there is left or right bundle branch block or pre-excitation present. In addition, increased voltage may indicate left or right ventricular hypertrophy. Are Q waves present, suggestive of infarction?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7492006\">",
"    <span class=\"h2\">",
"     Step 7: ST segment-T wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;Is there ST elevation or depression? Are the T waves inverted? (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    .) Abnormalities of the ST segment or T wave may represent myocardial ischemia or infarction, among other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7492052\">",
"    <span class=\"h2\">",
"     Step 8: Overall interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only after the prior steps have been completed should an overall interpretation and possible diagnoses be determined. This ensures assimilation of all information in the ECG and that no detail will be overlooked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RHYTHM ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpreting the rhythm of the ECG is sometimes difficult. However, as for ECG interpretation in general, a systematic approach along with a knowledge of arrhythmias often leads to a correct diagnosis. Calipers are extremely helpful for rhythm analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Step 1: Locate the P wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important and first step in rhythm interpretation is the identification of P waves and an analysis of their morphology. There are several questions that should be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are P waves visible? Each lead needs to be examined for P waves as they may not be obvious in some leads. On occasion, P waves may be located on or at the end of T waves and not obvious. They will therefore cause the T wave upslope or downstroke to no longer be smooth. It is also important to look for P waves during any pause in the rhythm. Absence of P waves may occur secondary to atrial fibrillation. Alternatively, P waves may be present but not visible if they are simultaneous with and buried within the QRS complex as in a junctional rhythm or AV nodal reentrant tachycardia. In addition, they may be located within the ST segment as with an AV reciprocating tachycardia or ventricular tachycardia. If a P wave is halfway between two QRS complexes, a second P wave is often buried within the QRS complex.",
"     </li>",
"     <li>",
"      What is the rate of the P waves (ie, the PP interval)? If the rate is less than 60, then a bradycardia is present. If the atrial or P wave rate is over 100, then a tachycardia is present. In general, sinus tachycardia occurs at rates of 100 to 180; atrial tachycardia, AV nodal reentrant tachycardia, or AV reciprocating tachycardia occur at rates of 140 to 220; atrial rates of 260-320 are seen with atrial flutter.",
"     </li>",
"     <li>",
"      What is the morphology and axis of the P waves? The normal sinus P wave is generally upright in leads I, II, aVF, and V4-V6. It will be negative in lead aVR. It may be negative or biphasic in leads III and V1. A negative P wave in the inferior leads or lead I suggests an ectopic rhythm (low atrial or left atrial respectively). Similarly, a completely positive P wave in V1 suggests a left atrial location.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Step 2: Establish the relationship between P waves and the QRS complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step is to determine the relationship between the P waves and the QRS complexes, addressing the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are the P waves associated with QRS complexes in a 1:1 fashion? If not, are there more or less P waves than QRS complexes and what are the atrial and ventricular rates? If there are more P waves than QRS complexes, then some form of AV block is present, which may be physiologic if there is a concomitant atrial tachycardia or flutter. If there are more QRS complexes than P waves, then the rhythm is an accelerated ventricular or junctional rhythm.",
"     </li>",
"     <li>",
"      Do the P waves precede each QRS complex as is the case with most normal rhythms? What is the PR interval, and is this interval fixed?",
"     </li>",
"     <li>",
"      Do P waves occur after each QRS complex (ie, retrograde P waves) as occurs in junctional or ventricular rhythms with retrograde VA conduction, or in AV nodal reentrant or AV reciprocating tachycardias? The RP interval should be noted and it should be established if it is fixed or variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often, establishing the relationship between the P wave and the QRS complex is the most important diagnostic step in rhythm interpretation. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Overall approach to rhythm analysis'",
"    </a>",
"    below.)&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Step 3: Analyze the QRS morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the QRS complexes are of normal duration (&lt;0.12 sec) and morphology, then the rhythm is supraventricular. It is essential to analyze the QRS in all 12 leads to be sure that it is normal.",
"   </p>",
"   <p>",
"    If the QRS is wide (ie, &gt;0.12 sec), then the rhythm is either supraventricular with aberrant conduction, pre-excitation, or ventricular pacing, or it is of ventricular origin. It may be possible to differentiate them by careful inspection of the QRS morphology, especially if the QRS morphology appears similar to the baseline QRS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18308?source=see_link\">",
"     \"Basic approach to delayed intraventricular conduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Step 4: Search for other clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the diagnosis of a rhythm disturbance can be made by clues provided by breaks in the rhythm or other irregularities in an otherwise regular rhythm. As an example, an increase in the degree of AV block as occurs with carotid sinus massage may unmask the flutter waves of atrial flutter.",
"   </p>",
"   <p>",
"    Capture beats and fusion beats may be the clues which help establish the diagnosis of ventricular tachycardia.",
"   </p>",
"   <p>",
"    The regularity of the QRS complexes should be established by asking the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do the QRS complexes occur with regular intervals or are they irregular?",
"     </li>",
"     <li>",
"      If the complexes are irregular, is there a pattern to the irregularity? Is the rhythm regularly irregular (ie, there is a repeating pattern of irregularity) or is the rhythm irregularly irregular without any pattern of irregularity? At least five supraventricular rhythms are irregularly irregular: sinus arrhythmia (in which there is only one P wave morphology and a stable PR interval); sinus rhythm with premature atrial contractions; sinus or other rhythm with variable AV block; multifocal atrial rhythm (wandering atrial pacemaker) when the rate is &lt;100 or multifocal atrial tachycardia with a rate &gt;100 (in which there are &ge;3 different P wave morphologies and PR intervals); or atrial fibrillation (in which there is no organized electrical activity).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Step 5: Interpret the rhythm in the clinical setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the clinical history, including drugs being taken, can be helpful in establishing a diagnosis. As an example, a regular wide complex rhythm in an older patient with a history of ischemic cardiomyopathy is most likely ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .) Similarly a narrow complex tachycardia of sudden onset in a young person with no medical history is likely AV nodal re-entrant or AV reciprocating tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the clinical presentation and associated hemodynamic findings do not necessarily correlate with the etiology of an abnormal rhythm. The presence of hemodynamic stability during a tachycardia, for example, does not imply a supraventricular etiology, nor does instability mean that the diagnosis is ventricular tachycardia. Hemodynamic changes are related to the rate of the arrhythmia and the presence and extent of underlying heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OVERALL APPROACH TO RHYTHM ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaching each new rhythm with a methodical standard as shown in the following algorithms permit the correct diagnosis to be established in most circumstances. An approach to the diagnosis of tachycardia and bradycardia is shown (",
"    <a class=\"graphic graphic_algorithm graphicRef77276 graphicRef52259 \" href=\"mobipreview.htm?4/40/4737\">",
"     algorithm 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef85685 graphicRef85684 \" href=\"mobipreview.htm?39/38/40544\">",
"     algorithm 1A-B",
"    </a>",
"    ). This issue is discussed in other ECG tutorials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=see_link\">",
"     \"ECG tutorial: Ventricular arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=see_link\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29077?source=see_link\">",
"     \"ECG tutorial: Rhythms and arrhythmias of the sinus node\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340807881\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is a graphical representation (time versus amplitude of electrical vector projection) of the electrical activity of the heart. While imperfect as a diagnostic or prognostic tool, it contains a wealth of information necessary for the proper care of the patient with potential cardiovascular disease.",
"   </p>",
"   <p>",
"    The electrical activity of each normal cardiac cycle is represented in sequence by the P wave, the PR interval, the QRS complex, the ST segment, the T wave, and (sometimes) the U wave. The following pieces of information should be evaluated for each of these.",
"   </p>",
"   <p>",
"    A systematic approach to interpretation of the ECG is critically important. (See",
"    <a class=\"local\" href=\"#H7491801\">",
"     'Approach to ECG interpretation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rate &mdash; Is the rate between 60 and 100? (See",
"      <a class=\"local\" href=\"#H7491826\">",
"       'Step 1: Rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rhythm &mdash; Is it normal sinus or other? (See",
"      <a class=\"local\" href=\"#H7491838\">",
"       'Step 2: Rhythm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Axis &mdash; Is there axis deviation? (See",
"      <a class=\"local\" href=\"#H7491872\">",
"       'Step 3: Axis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intervals &mdash; Are all intervals normal? (See",
"      <a class=\"local\" href=\"#H7491898\">",
"       'Step 4: Intervals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P wave &mdash; What is its height, width, and axis? (See",
"      <a class=\"local\" href=\"#H7491935\">",
"       'Step 5: P wave'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      QRS complex &mdash; Are there pathologic Q waves, bundle branch block, or chamber hypertrophy? (See",
"      <a class=\"local\" href=\"#H7491985\">",
"       'Step 6: QRScomplex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ST-T waves &mdash; Is it isoelectric, elevated, or depressed relative to the TP segment? (See",
"      <a class=\"local\" href=\"#H7492006\">",
"       'Step 7: ST segment-T wave'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall interpretation &mdash; What is the diagnosis? (See",
"      <a class=\"local\" href=\"#H7492052\">",
"       'Step 8: Overall interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7491223\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/1\">",
"      Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72:17B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/2\">",
"      Fridericia L. Die systolendauer im Elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 1920; 53:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/3\">",
"      Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72:23B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/4\">",
"      Sagie A, Larson MG, Goldberg RJ, et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992; 70:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/5\">",
"      Malik M, F&auml;rbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/6\">",
"      Manion CV, Whitsett TL, Wilson MF. Applicability of correcting the QT interval for heart rate. Am Heart J 1980; 99:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/7\">",
"      Rautaharju PM, Zhang ZM, Prineas R, Heiss G. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 2004; 93:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/8\">",
"      Hopenfeld B, Ashikaga H. Origin of the electrocardiographic U wave: effects of M cells and dynamic gap junction coupling. Ann Biomed Eng 2010; 38:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37687/abstract/9\">",
"      Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:976.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2115 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37687=[""].join("\n");
var outline_f36_51_37687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H340807881\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECG GRID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLEXES AND INTERVALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      P wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PR interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      QRS complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ST segment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      T wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      QT interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      U wave",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEART RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7491801\">",
"      APPROACH TO ECG INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7491826\">",
"      Step 1: Rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7491838\">",
"      Step 2: Rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7491872\">",
"      Step 3: Axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7491898\">",
"      Step 4: Intervals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7491935\">",
"      Step 5: P wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7491985\">",
"      Step 6: QRScomplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7492006\">",
"      Step 7: ST segment-T wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7492052\">",
"      Step 8: Overall interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RHYTHM ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Step 1: Locate the P wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Step 2: Establish the relationship between P waves and the QRS complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Step 3: Analyze the QRS morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Step 4: Search for other clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Step 5: Interpret the rhythm in the clinical setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OVERALL APPROACH TO RHYTHM ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H340807881\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7491223\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2115|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?18/24/18830\" title=\"algorithm 1A\">",
"      Approach to bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/22/4463\" title=\"algorithm 1B\">",
"      Approach to tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?17/38/18031\" title=\"algorithm 2A\">",
"      P wave before QRS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?10/57/11166\" title=\"algorithm 2B\">",
"      P wave before QRS II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2115|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18641\" title=\"figure 1\">",
"      ECG grid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/56/21389\" title=\"figure 2\">",
"      ECG complex and intervals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/54/41838\" title=\"figure 3\">",
"      Calculation of frontal plane axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2115|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?22/55/23417\" title=\"waveform 1\">",
"      J point",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18308?source=related_link\">",
"      Basic approach to delayed intraventricular conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=related_link\">",
"      ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29077?source=related_link\">",
"      ECG tutorial: Rhythms and arrhythmias of the sinus node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16886?source=related_link\">",
"      Left anterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16420?source=related_link\">",
"      Left posterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2086?source=related_link\">",
"      Normal sinus rhythm and sinus arrhythmia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_51_37688="Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis";
var content_f36_51_37688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37688/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37688/contributors\">",
"     Mark A Jacobson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37688/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37688/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/51/37688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) retinitis is the most common serious ocular complication of AIDS. The majority of disease is related to reactivation of latent infection. However, the introduction of highly active antiretroviral therapy has led to changes in the incidence, natural history, management, and sequelae of CMV retinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, pathogenesis, risk factors, and diagnosis of CMV retinitis are discussed here. The treatment of CMV retinitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13337?source=see_link\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CMV IN THE ERA OF HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV retinitis was first reported as a complication of AIDS in 1982. Prior to the availability of highly active antiretroviral therapy (HAART), CMV retinitis occurred in 21 to 44 percent of patients with AIDS, primarily in those with a CD4 T lymphocyte count below",
"    <span class=\"nowrap\">",
"     50/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    of blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In early case series, patients who survived beyond six months without CMV-specific treatment became severely visually impaired or blind. Median time to progression on CMV-specific antiviral therapy was 47 to 104 days, mean survival after diagnosis was 6 to 10 months, and indefinite maintenance therapy was essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the introduction of HAART has had a dramatic impact on CMV disease in the HIV-infected patient. At present, CMV disease only occurs in patients with advanced immunosuppression, who are either not receiving or have failed to respond to antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era prior to the availability of potent ART, the incidence of CMV retinitis was high. As an example, in one observational study, approximately 25 percent of AIDS patients with a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    developed CMV retinitis during four years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, in the placebo arm of a clinical trial of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    prophylaxis, which enrolled AIDS patients with a CD4 count of &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or patients with a history of an AIDS-defining opportunistic infection and a CD4 count &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    the incidence of CMV retinitis was 24 percent after only 12 months of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the incidence of CMV retinitis has decreased by 80 percent since potent ART became available and survival after diagnosis has increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. This trend has been described in the United States and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study was performed of 1600 AIDS patients who were seen every six months for ophthalmic examination from 1996 to 2009 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/10\">",
"       10",
"      </a>",
"      ]. The incidence rate of CMV retinitis was",
"      <span class=\"nowrap\">",
"       0.36/100",
"      </span>",
"      person-years based upon 29 incident cases during 8134 person-years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/10\">",
"       10",
"      </a>",
"      ]. The four-year incidence rate of CMV retinitis was 12 percent, a 52 percent reduction compared with historical data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effect of antiretroviral therapy on CMV end-organ disease was examined within a multicenter European cohort study during the years 1994 to 2001 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/9\">",
"       9",
"      </a>",
"      ]. Of patients with a baseline CD4 count of &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      the risk of developing CMV disease was significantly lower in those receiving potent antiretroviral therapy (1.8 percent on HAART, 11 percent on dual therapy, and 14 percent without treatment). Eighteen percent of all deaths were specifically caused by end-organ CMV disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CMV retinitis is also an important complication of AIDS internationally, reported in up to 8.5 percent of AIDS patients in parts of Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/11\">",
"     11",
"    </a>",
"    ], 15 percent in Thailand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/12\">",
"     12",
"    </a>",
"    ], and 17 percent in India [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect on clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of HAART may also lead to different clinical presentations of symptomatic CMV disease, in the setting of immune reconstitution:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients may present with CMV retinitis in the setting of higher CD4 counts (&gt;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      secondary to early immunologic recovery of T-cells after initiation of HAART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/14\">",
"       14",
"      </a>",
"      ]. This emphasizes the fact that early immune reconstitution is \"incomplete\" and the patient is still at risk for opportunistic infections early during treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/15\">",
"       15",
"      </a>",
"      ]. Thus, clinicians should not eliminate the possibility of CMV retinitis simply based on a relatively high CD4 count.",
"     </li>",
"     <li>",
"      Some patients who have quiescent CMV retinitis (or subclinical CMV retinal infection) at the time potent antiretroviral therapy is initiated, subsequently develop new areas of retinal opacification within the first months after responding to antiretroviral treatment with a rise in their absolute CD4+ T cell counts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/14\">",
"       14",
"      </a>",
"      ]. These new retinal lesions are either located on the border of previous healed lesions or may be the initial clinical presentation of CMV retinitis. In patients already on maintenance anti-CMV therapy, this new retinal opacification does not signify a failure of the anti-CMV therapy or antiretroviral therapy, and the lesions subsequently heal with continuation of the same anti-CMV regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of HAART was also associated with decreased morbidity and mortality related to ocular involvement, slower rates of retinal progression, ocular complications, and improved survival after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the pre-HAART era the rates of visual loss in eyes were substantial. The two major causes of visual loss were retinitis, involving either the macula or the optic nerve, and retinal detachment. In the HAART era, visual outcomes improved significantly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, the overall rate of progression of retinitis in the HAART era is significantly slower than in the pre-HAART era [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/20\">",
"       20",
"      </a>",
"      ]. However, patients with CMV retinitis who initiate HAART are also at risk of developing an ocular inflammatory syndrome, termed immune recovery uveitis, which can cause substantial vision loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'CMV immune recovery uveitis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use of HAART has also been associated with a decreased incidence of CMV retinitis in the uninvolved second eye [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/22\">",
"       22",
"      </a>",
"      ]. In a study of 376 consecutive patients with AIDS and unilateral CMV retinitis, subjects were followed for the development of second-eye retinitis. The use of HAART was associated with a 46 percent reduction in incidence of retinitis in the uninvolved eye compared to untreated patients. Rates of retinal detachment have also been reduced compared to historical controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of 103 consecutive patients diagnosed with CMV retinitis between 1990 and 1998 demonstrated that survival following diagnosis increased from a median of 0.65 years prior to 1995 to a median of 1.07 years following this date. However, subsequent data suggest more dramatic results. Five year follow-up of 15 patients after diagnosis with CMV retinitis found that all patients were alive and continued to have rising CD4 T cell counts throughout the follow-up period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large observational cohort of 1583 AIDS patients who were enrolled between 1998 and 2003, mortality rates among patients with a baseline CD4+ T-cell count &gt;100 cells were similar in those with or without a history of CMV retinitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that with appropriate therapy, survival times after the diagnosis of CMV retinitis have significantly changed since the era of HAART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CMV specific immune responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HAART clearly leads to restoration of immune protection against further progression of CMV retinitis in nearly all CMV retinitis patients who respond to potent antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/16,24,26,27\">",
"     16,24,26,27",
"    </a>",
"    ], it is not clear whether HAART leads to complete restoration of CMV-specific CD4+ and CD8+ T cell responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, in one longitudinal study of a CMV-specific CD8+ interferon gamma cytokine flow cytometry assay, immune responses in 10 patients with active CMV retinitis were compared to 20 patients who had a history of CMV retinitis and who successfully discontinued maintenance therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/28\">",
"       28",
"      </a>",
"      ]. CD8+ T cell responses were demonstrated in only 3 of 10 patients with active CMV retinitis compared to all 20 patients with a past history of CMV, suggesting full restoration of this critical CMV-specific T cell response.",
"     </li>",
"     <li>",
"      In an observational study of 87 patients with CD4 T counts less than 50 cells, positive baseline CMV-specific interferon gamma responses identified by ELISPOT (enzyme-linked immunospot) assay, were associated with delayed development of CMV viremia, end-organ disease, and death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/29\">",
"       29",
"      </a>",
"      ]. Factors associated with positive ELISPOT results were higher CD4 T cell counts, lower HIV RNA levels, and longer duration of HAART. However, reconstitution of CMV-specific CD4+ and CD8+ T cell responses (as measured by flow cytometry) were not observed during the study.",
"     </li>",
"     <li>",
"      Another study identified three CMV-specific T cell parameters that discriminated between patients with active CMV retinitis and those who had full clinical recovery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/32\">",
"       32",
"      </a>",
"      ]. However, when these parameters were examined in a large, longitudinal study, they were not useful in predicting risk of developing CMV retinitis in patients with AIDS, possibly because the interval between the decrease in critical CMV-specific T cell subsets and the onset of retinitis was very short [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies support the hypothesis that CMV retinitis results from hematogenous spread of CMV to the eye. Studies in transplant recipients and patients with AIDS indicate that CD4-dependent cytotoxic T lymphocyte activity of CMV antigen-specific CD8+ T cells is critical for preventing CMV replication and end-organ disease, and that impaired CD4 cell function or number is the key immune deficit that permits uncontrolled CMV replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/28,34,35\">",
"     28,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most cases of CMV retinitis occur in patients with a CD4 count below",
"    <span class=\"nowrap\">",
"     50/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    patients may be predisposed before such severe CD4 cell depletion as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a longitudinal, prospective study, patients with AIDS who subsequently developed CMV retinitis had lower T-cell proliferative responses (in an assay that primarily measured CD4+ T cell proliferation) to CMV both early and late in disease, compared to patients who did not develop retinitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/36\">",
"       36",
"      </a>",
"      ]. Genetic factors may contribute to this predisposition since low responses to CMV were more common in those with HLA B44 and DR7.",
"     </li>",
"     <li>",
"      A longitudinal study analyzed the dynamics of CMV-specific CD8+ and CD4+ T cell responses in parallel with CMV DNA in 19 HIV-infected patients, 10 of whom had progression to CMV end-organ disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/37\">",
"       37",
"      </a>",
"      ]. In individuals progressing to end-organ disease, CMV-specific IFN-gamma producing CD4+ T cells disappeared during the year before onset of clinical disease. This decline was accompanied by a sharp increase in CMV DNA before symptom onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there may be other genetic predispositions to developing CMV retinitis. For example, CMV contains a human interleukin-10 (IL-10) homolog in its genome to evade host immune reactions. Variants of the human IL-10 receptor may influence susceptibility to developing CMV retinitis in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV retinitis is characterized histologically by full-thickness retinal necrosis and edema that is subsequently replaced by thin, atrophic scar tissue. This scar tissue is susceptible to tearing, which can lead to subsequent retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/39\">",
"     39",
"    </a>",
"    ]. Without antiviral treatment or immune reconstitution, the retinal lesions enlarge centrifugally. The portions of the retina destroyed by CMV do not regenerate functionally. Thus, the goal of therapy for CMV retinitis is to prevent further retinal necrosis and loss of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CMV viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CMV virus in blood (as measured by culture, CMV DNA amplification, or antigen detection) has been studied as a risk factor for the development of CMV retinitis in patients with AIDS with varying results in the pre- and post-HAART eras.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pre-HAART era",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies in the pre-HAART era suggested a close association between CMV viremia and risk of CMV disease and mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One early study demonstrated that CMV DNA load was an independent marker of CMV disease and survival and was more predictive than HIV-1 RNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/40\">",
"       40",
"      </a>",
"      ]. In addition, patients who attained CMV viral suppression with pre-emptive oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      therapy had a significantly lower risk of developing CMV disease and higher rates of survival.",
"     </li>",
"     <li>",
"      In a large study of 619 AIDS patients, a positive plasma CMV DNA PCR was associated with a 2.5-fold increased risk of death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/41\">",
"       41",
"      </a>",
"      ]. Furthermore, each log(10) increase in baseline CMV DNA load was associated with a threefold increase in CMV disease and a twofold increase in mortality. However, 14 percent of individuals without detectable plasma CMV DNA at entry developed CMV end organ disease as well.",
"     </li>",
"     <li>",
"      In another study of 108 patients with CMV retinitis, 81 percent had either a positive blood or urine culture for CMV at the time of presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/42\">",
"       42",
"      </a>",
"      ]. Other risk factors include advanced immunosuppression (CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      prior opportunistic infections, and a high plasma HIV RNA level of &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HAART era",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized , placebo-controlled trial was performed in 338 patients with advanced AIDS, most of whom were taking ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients had serial measurements of CMV DNA by PCR and indirect ophthalmoscopy every eight weeks. Those with onset of CMV viremia were randomly assigned to either induction or maintenance doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    or placebo. The following results were reported in preliminary form:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixty-eight (20 percent) developed viremia, of whom 47 entered the treatment phase of the study.",
"     </li>",
"     <li>",
"      There was no significant difference in rates of CMV end-organ disease or death between treatment arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the lack of benefit of pre-emptive therapy, this study highlights the much lower prevalence of CMV disease in patients who are taking HAART compared to rates of 50 percent that were documented in the pre-HAART era.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Iatrogenic risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic risk factors (corticosteroids use, chemotherapy, radiotherapy and blood transfusions) for CMV retinitis were evaluated in a case-control study of 120 patients with CMV retinitis and 159 control patients, all of whom had AIDS and a CD4 T-cell &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/46\">",
"     46",
"    </a>",
"    ]. Among the risk factors studied, only corticosteroid use was predictive of CMV retinitis (odds ratio 6.41, 95 percent CI 2.35-17.51).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV retinitis can cause blurring or loss of central vision, scotomata (\"blind spots\"), floaters, or photopsia (\"flashing lights\"), depending upon the anatomic site of retinal destruction and whether or not retinal detachment has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/39\">",
"     39",
"    </a>",
"    ]. A complaint of floaters or photopsia is the single most powerful symptomatic predictor of CMV retinitis in an AIDS patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/47\">",
"     47",
"    </a>",
"    ] and should always be evaluated with dilated ophthalmoscopy. Lesions close to or involving the fovea or optic nerve are particularly likely to cause serious visual impairment. Acute loss of vision can occur if retinitis leads to retinal detachment.",
"   </p>",
"   <p>",
"    CMV retinitis usually occurs as unilateral disease, but in the absence of therapy, involvement of the contralateral eye will often occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal detachment is one of the major causes of vision loss in patients with CMV retinitis. Although the retina can be reattached anatomically by surgery, postoperative visual acuity is almost never as good as it was before detachment occurred. Peripheral (ie, anterior) retinal lesions underlie the vitreous base, where the vitreous body is normally adherent to the retina. Thus, large peripheral lesions are associated with an increased risk of retinal detachment.",
"   </p>",
"   <p>",
"    In addition, some patients experiencing the immune reconstitution syndrome have developed a number of other ocular complications, including anterior uveitis, vitritis, and cystoid macular edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'CMV immune recovery uveitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV retinitis is generally diagnosed by an experienced ophthalmologist on the basis of characteristic retinal changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/48\">",
"     48",
"    </a>",
"    ]. Indirect ophthalmoscopy reveals yellow-white, fluffy, or granular retinal lesions, often located close to retinal vessels and associated with hemorrhage. In the absence of antiretroviral therapy, CMV retinitis is associated with little inflammation of the vitreous; retinitis invariably progresses without treatment, usually within 10 to 21 days after presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions can be described as \"fulminant and edematous\" versus \"indolent and granular\" based on several factors, including the degree of retinal opacity (whitening), retinal hemorrhage, and lesion shape and location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/49\">",
"     49",
"    </a>",
"    ]. One retrospective observational study of 100 AIDS patients with untreated CMV retinitis suggested that lesion opacity may be a surrogate of disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/49\">",
"     49",
"    </a>",
"    ]. The intensity of the white opaque borders is thought to represent virus activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small lesions may be difficult to differentiate from benign cotton wool spots; as a result, serial funduscopic examinations are sometimes required to make the diagnosis. The rate of enlargement of CMV lesions toward the fovea is slow but gradual. It is therefore safe to perform frequent examinations to confirm uncertain diagnoses before initiating therapy.",
"   </p>",
"   <p>",
"    The presence of serum antibodies to CMV is not diagnostically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/44\">",
"     44",
"    </a>",
"    ]. A negative IgG CMV antibody indicates that CMV is unlikely to be the etiology of retinitis. However, on rare occasion a patient with advanced HIV and prior CMV infection may serorevert from antibody-positive to antibody-negative. Thus, a negative CMV IgG antibody significantly lowers the diagnostic possibility of CMV, but does not completely eliminate it from consideration.",
"   </p>",
"   <p>",
"    The clinical syndrome of immune recovery uveitis may present with similar symptoms as the initial episode of CMV retinitis, but can be distinguished by a full ophthalmologic examination. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'CMV immune recovery uveitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CMV IMMUNE RECOVERY UVEITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an initial period of treatment with anti-CMV therapy and HAART, patients may develop significant intraocular inflammation secondary to immune recovery. This entity is known as immune recovery uveitis (IRU) and can lead to significant ocular morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/1,21,26,51-53\">",
"     1,21,26,51-53",
"    </a>",
"    ]. Complications of IRU now account for approximately 50 percent of incident vision loss among patients with longstanding CMV retinitis and immune recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uveitis is a general term that refers to inflammation in the eye; vitritis refers to inflammation within the vitreous cavity and is a subset of uveitis. Immune recovery uveitis is associated with vitreous inflammation with or without cystoid macular edema, epiretinal membrane, or retinal neovascularization in patients with HAART-mediated immune recovery and inactive CMV retinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/1,55-57\">",
"     1,55-57",
"    </a>",
"    ]. Although some patients develop transient vitritis soon after initiating HAART and quickly recover normal visual function, IRU that leads to macular edema can often be associated with a significant decline in visual acuity despite successful treatment of CMV retinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/21,57-59\">",
"     21,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of IRU is not well understood, but may be related to T-cell mediated immune reconstitution to latent CMV intraocular antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/26,51,57,60\">",
"     26,51,57,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .) Symptoms include floaters, blurred vision, or photophobia. Patients may also develop other inflammatory complications such as cataract, glaucoma, and vitreous hemorrhage; neovascularization can occur as a late complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/51,56,61,62\">",
"     51,56,61,62",
"    </a>",
"    ]. In a study of 54 patients with CMV retinitis, the onset of IRU occurred within 2 to 84 weeks (median 20 weeks) after an improvement of CD4 cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 374 patients with AIDS and CMV retinitis affecting 539 eyes, 36 patients (9.6 percent) developed IRU involving 50 eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/21\">",
"     21",
"    </a>",
"    ]. Risk factors included prior CMV involvement of greater than 25 percent of the retina, involvement of the posterior pole of the eye, or treatment with intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    . No patient with IRU was observed to have active retinitis or detectable CMV DNA in peripheral blood. The extent of prior CMV retinitis and the use of either systemic or intravitreal cidofovir has been identified as a potential cofactor in IRU in other studies as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37688/abstract/52,57,63,64\">",
"     52,57,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any patient with a history of immune recovery, quiescent CMV retinitis, and new visual symptoms, should be referred promptly for ophthalmic examination to evaluate for CMV progression, relapse, or immune recovery uveitis. On ophthalmologic examination, IRU is characterized by inflammation in the anterior chamber and vitreous cavity, which is best diagnosed with a combination of slit lamp examination and indirect ophthalmoscopy.",
"   </p>",
"   <p>",
"    The treatment of IRU is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13337?source=see_link\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) retinitis is the most common serious ocular complication of AIDS. The majority of disease is related to reactivation of latent infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for CMV retinitis include a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      history of prior opportunistic infection, high HIV RNA level, and CMV viremia.",
"     </li>",
"     <li>",
"      The introduction of HAART has been associated with a decreased incidence of CMV retinitis, lower rates of ocular complications, and improved survival after diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'CMV in the era of HAART'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV retinitis can cause blurring or loss of central vision, scotomata (\"blind spots\"), floaters, or photopsia (\"flashing lights\"). Complications include retinal detachment with complete visual loss. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV retinitis is generally diagnosed by an experienced ophthalmologist on the basis of characteristic retinal changes. Indirect ophthalmoscopy reveals yellow-white, fluffy, or granular retinal lesions, often located close to retinal vessels and associated with hemorrhage. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A positive CMV antibody is not helpful diagnostically in the acute setting; a negative CMV antibody lowers the diagnostic possibility but does not eliminate CMV infection from consideration.",
"     </li>",
"     <li>",
"      After an initial period of treatment with anti-CMV therapy and HAART, patients may present with visual blurring, floaters, or decreased visual acuity. If this occurs, the patient should be evaluated by an ophthalmologist to determine if these symptoms are related to CMV progression, relapse, or an immune reconstitution inflammatory syndrome, since their clinical management and treatment will differ. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'CMV in the era of HAART'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'CMV immune recovery uveitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13337?source=see_link\">",
"       \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/1\">",
"      Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina 2005; 25:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/2\">",
"      Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/3\">",
"      Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/4\">",
"      Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992; 326:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/5\">",
"      Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002; 133:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/6\">",
"      Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996; 114:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/7\">",
"      Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/8\">",
"      Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008; 145:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/9\">",
"      Yust I, Fox Z, Burke M, et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004; 23:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/10\">",
"      Sugar EA, Jabs DA, Ahuja A, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2012; 153:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/11\">",
"      Kestelyn P. The epidemiology of CMV retinitis in Africa. Ocul Immunol Inflamm 1999; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/12\">",
"      Ausayakhun S, Watananikorn S, Ittipunkul N, et al. Epidemiology of the ocular complications of HIV infection in Chiang Mai. J Med Assoc Thai 2003; 86:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/13\">",
"      Biswas J, Madhavan HN, George AE, et al. Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol 2000; 129:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/14\">",
"      Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/15\">",
"      Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001; 183:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/16\">",
"      Deayton JR, Wilson P, Sabin CA, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/17\">",
"      Roels P. Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART). Optometry 2004; 75:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/18\">",
"      Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003; 121:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/19\">",
"      Holbrook JT, Jabs DA, Weinberg DV, et al. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol 2003; 121:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/20\">",
"      Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology 2004; 111:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/21\">",
"      Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 2006; 113:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/22\">",
"      Kempen JH, Jabs DA, Wilson LA, et al. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol 2005; 139:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/23\">",
"      Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology 2004; 111:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/24\">",
"      Sklar PA, Agyemang AF, Monastra R, et al. Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis. AIDS 2004; 18:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/25\">",
"      Jabs DA, Holbrook JT, Van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2005; 112:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/26\">",
"      Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 2000; 283:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/27\">",
"      Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 2005; 6:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/28\">",
"      Jacobson MA, Maecker HT, Orr PL, et al. Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J Infect Dis 2004; 189:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/29\">",
"      Weinberg A, Tierney C, Kendall MA, et al. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J Infect Dis 2006; 193:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/30\">",
"      Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/31\">",
"      Keane NM, Price P, Lee S, et al. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med 2004; 5:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/32\">",
"      Sinclair E, Tan QX, Sharp M, et al. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. J Infect Dis 2006; 194:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/33\">",
"      Jacobson MA, Tan QX, Girling V, et al. Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis 2008; 46:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/34\">",
"      Rook AH, Manischewitz JF, Frederick WR, et al. Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome. J Infect Dis 1985; 152:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/35\">",
"      Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/36\">",
"      Schrier RD, Freeman WR, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group. J Clin Invest 1995; 95:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/37\">",
"      Bronke C, Palmer NM, Jansen CA, et al. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005; 191:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/38\">",
"      Sezgin E, Jabs DA, Hendrickson SL, et al. Effect of host genetics on the development of cytomegalovirus retinitis in patients with AIDS. J Infect Dis 2010; 202:606.",
"     </a>",
"    </li>",
"    <li>",
"     Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Ocular Infection and Immunity, Pepose JS, Holland GN, Wilhelmus KR (Eds), CV Mosby, St. Louis 1996. p.1088.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/40\">",
"      Spector SA, Hsia K, Crager M, et al. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999; 73:7027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/41\">",
"      Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998; 101:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/42\">",
"      Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998; 177:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/43\">",
"      Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993; 116:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/44\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/45\">",
"      Wohl DA, Kendall MA, Andersen J, et al. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials 2009; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/46\">",
"      Hodge WG, Boivin JF, Shapiro SH, et al. Iatrogenic risk factors for cytomegalovirus retinitis. Can J Ophthalmol 2005; 40:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/47\">",
"      Hodge WG, Boivin JF, Shapiro SH, et al. Clinical risk factors for cytomegalovirus retinitis in patients with AIDS. Ophthalmology 2004; 111:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/48\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/49\">",
"      Holland GN, Vaudaux JD, Jeng SM, et al. Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994). Am J Ophthalmol 2008; 145:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/50\">",
"      Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 1989; 107:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/51\">",
"      Goldberg DE, Wang H, Azen SP, Freeman WR. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol 2003; 87:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/52\">",
"      Holland GN. Immune recovery uveitis. Ocul Immunol Inflamm 1999; 7:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/53\">",
"      Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000; 129:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/54\">",
"      Thorne JE, Jabs DA, Kempen JH, et al. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 2006; 113:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/55\">",
"      Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 2006; 26:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/56\">",
"      Robinson MR, Csaky KG, Lee SS, et al. Fibrovascular changes misdiagnosed as cytomegalovirus retinitis reactivation in a patient with immune recovery. Clin Infect Dis 2004; 38:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/57\">",
"      Karavellas MP, Azen SP, MacDonald JC, et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 2001; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/58\">",
"      Raina J, Bainbridge JW, Shah SM. Decreased visual acuity in patients with cytomegalovirus retinitis and AIDS. Eye (Lond) 2000; 14 ( Pt 1):8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/59\">",
"      Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998; 125:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/60\">",
"      Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999; 83:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/61\">",
"      Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999; 179:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/62\">",
"      Wright ME, Suzman DL, Csaky KG, et al. Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis. Clin Infect Dis 2003; 36:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/63\">",
"      Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 2003; 23:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37688/abstract/64\">",
"      Song MK, Azen SP, Buley A, et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 2003; 136:696.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3746 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-9B24B61484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37688=[""].join("\n");
var outline_f36_51_37688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CMV IN THE ERA OF HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect on clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CMV specific immune responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CMV viremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pre-HAART era",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HAART era",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Iatrogenic risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CMV IMMUNE RECOVERY UVEITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13337?source=related_link\">",
"      Treatment of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_51_37689="Sexually transmitted diseases: Overview of issues specific to adolescents";
var content_f36_51_37689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sexually transmitted diseases: Overview of issues specific to adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     J Dennis Fortenberry, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37689/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/51/37689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescence is a heterogeneous developmental period in terms of sexual behavior and risk of acquiring sexually transmitted diseases (STD). Early adolescence begins during the first years of the second decade and is marked by rapid physical growth and attainment of secondary sex characteristics. Middle adolescence begins at approximately age 14 years, ends around age 17 to 18 years, and is marked by maturation of the reproductive systems and achievement of adult physical stature. Increased sexual interest and noncoital sexual behaviors are characteristic of middle adolescence.",
"   </p>",
"   <p>",
"    The average age of first coitus is approximately 16 years among American adolescents, but the age is lower in certain populations, such as inner city youth. Late adolescence ends with the transition into young adulthood and is associated with high levels of sexual activity and acquisition of STD.",
"   </p>",
"   <p>",
"    This topic will focus on aspects of sexually transmitted diseases that are particularly relevant in adolescents. Details about clinical manifestations, diagnosis, and treatment of individual infections are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional data from the 2003-2004 National Health and Nutrition Examination Survey (NHANES) indicate 24 percent of female adolescents aged 14 to 19 years had laboratory evidence of at least one of the following sexually transmitted diseases (STD): human papillomavirus (HPV, 18 percent),",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    (4 percent), T",
"    <em>",
"     richomonas vaginalis",
"    </em>",
"    (3 percent), herpes simplex virus type 2 (HSV-2, 2 percent), or",
"    <em>",
"     Neisseria gonorrhoeae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/1\">",
"     1",
"    </a>",
"    ]. Among girls who reported ever having had sex, 40 percent had laboratory evidence of one of the four STD, predominantly HPV (30 percent) and chlamydia (7 percent).",
"   </p>",
"   <p>",
"    The acquisition of genital gonorrhea remained steady among adolescent females (age 15 to 19 years) between 2010 and 2011 (557.6 and 556.5 per 100,000 population, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/2\">",
"     2",
"    </a>",
"    ]. Genital chlamydia rates among 15- to 19-year-old women were considerably higher, at 3416.5 cases per 100,000 in 2011.",
"   </p>",
"   <p>",
"    Repeated acquisition of STD is common: as many as 40 percent of the annual incidence of chlamydial or gonococcal disease occurs in adolescents previously infected with the causative organisms. Many adolescents are reinfected within a few months of an index infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details about human immunodeficiency virus (HIV) infections in adolescents may be found elsewhere. However, it is important to note that HIV is primarily an STD among adolescents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/44/1737?source=see_link\">",
"     \"The adolescent with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Behavioral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral factors have been linked to the increased risk of acquisition of sexually transmitted diseases (STD) among adolescents, but biologic factors also may play a role.",
"   </p>",
"   <p>",
"    Among the behavioral factors that have been associated with acquisition of STD in adolescents are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Time elapsed since first intercourse, particularly for human papillomavirus (HPV). In an observational study of urban females (14 to 17 years at enrollment), 25 percent were diagnosed with an STD within one year of first intercourse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/4\">",
"       4",
"      </a>",
"      ]. Repeated infections were common. These findings highlight the need for initiation of STD screening within one year of first intercourse and of retesting individuals who have been infected every three to four months. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Screening and diagnostic testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Sexual activity within early and middle adolescence, particularly for",
"      <em>",
"       C. trachomatis",
"      </em>",
"      infection; 29 percent of sexually active inner-city adolescent females in one study tested positive for Chlamydia, with 14-year-old adolescents having the highest age-specific prevalence.",
"     </li>",
"     <li>",
"      Multiple partners.",
"     </li>",
"     <li>",
"      New partners.",
"     </li>",
"     <li>",
"      Partners with multiple other partners.",
"     </li>",
"     <li>",
"      Inconsistent use of condoms, especially with established partners.",
"     </li>",
"     <li>",
"      Alcohol and other drug consumption (although this factor may track with poor contraceptive use or multiple partners, rather than serving as an independent marker of risky behavior).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surveys of risk behaviors among high school students have shown a decline in sexual experience and the prevalence of multiple sexual partners of 16 and 24 percent, respectively, over the decade from 1991 to 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/11\">",
"     11",
"    </a>",
"    ]. The prevalence of condom use increased significantly between 1991 and 1999 and then plateaued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biologic factors have been hypothesized to influence the susceptibility of adolescents to acquisition of STD. One such factor is cervical ectopy or cervical immaturity, which refers to the area of ectocervix that is covered by columnar epithelium after puberty. Columnar epithelium is thought to be more susceptible than is squamous epithelium (that replaces columnar upon maturation) to sexually transmitted organisms such as",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    ,",
"    <em>",
"     C. trachomatis",
"    </em>",
"    , and HPV. However, one study could not demonstrate an independent association of cervical ectopy with STD among adolescent women and, in fact, noted that an increased number of lifetime partners was associated with a more mature cervix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secretory IgA (sIgA), a local protective antibody, is another postulated biologic factor. Adolescents had slightly lower levels of sIgA in cervical mucus than did adult women in one small study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/13\">",
"     13",
"    </a>",
"    ]. Another study addressing whether sIgA levels were higher in the secretory phase of the menstrual cycle (a phase that frequently is absent in early adolescence, when ovulation may not occur or may occur irregularly) found no difference in levels in different phases of the adolescent menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UNIQUE ISSUES IN ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and treatment of sexually transmitted disease (STD) in adolescents raises a number of unique issues, including consent for diagnosis and treatment, confidentiality, parental notification, and mandatory reporting of sexual activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-consent for diagnosis and treatment of STD is recognized in all 50 states. However, state laws vary in terms of the specific infections defined as sexually transmitted. This issue becomes more vague and complex in situations for which surgical therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hospitalization are required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=see_link\">",
"       \"Consent in adolescent health care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concerns about privacy and confidentiality are important barriers to seeking medical care among adolescents with possible STD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/15\">",
"       15",
"      </a>",
"      ]. Specific discussion of the meaning and limits of confidentiality increases disclosure of sensitive information about symptoms, sexual activity, sexual partners, and preventive behaviors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link\">",
"       \"Confidentiality in adolescent health care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy or fear of pregnancy sometimes motivates care-seeking with a chief complaint of genital symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/31/10744?source=see_link&amp;anchor=H3#H3\">",
"       \"Pregnancy in adolescents\", section on 'Diagnosis of pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most states have \"age of consent\" laws that require notification of child protection authorities if sexual activity is identified, especially if there are large discrepancies in the partners' ages. Ages vary among the states. Large age discrepancies (&gt;5 years) between partners are seen in approximately one-third of adolescents with first sexual intercourse very early in adolescence (ie, ages 11 or 12 years) and in approximately one-tenth of adolescents who have their first intercourse in middle or late adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link&amp;anchor=H8#H8\">",
"       \"Confidentiality in adolescent health care\", section on 'Consensual sexual activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In surveys, physical and sexual violence from dating partners are reported by as many as 20 percent of adolescent girls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. However, such acts are infrequently reported to clinicians; questions regarding physical and sexual dating violence should be included in clinical assessments of sexual behavior and STD risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Self-treatment with topical medications, antibiotics, or douching is reported by as many as 25 percent of adolescents with STD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/21\">",
"       21",
"      </a>",
"      ]. Symptomatic adolescent females take approximately 10 days on average to seek care compared with only approximately six days for symptomatic males [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reporting of some STD is mandatory in all states, although the specific organisms vary. Syphilis, gonorrhea, and acquired immunodeficiency syndrome are reportable diseases in every state [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iowa requires parental notification for HIV infection; the remaining states do not require parental notification, although notification is not expressly forbidden. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link&amp;anchor=H12#H12\">",
"       \"Confidentiality in adolescent health care\", section on 'Sexually transmitted infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacists or other medical personnel may inadvertently compromise confidentiality. A study from Indiana University shows that 30 percent of pharmacists would call parents about a prescription for antibiotics used to treat STD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link&amp;anchor=H15#H15\">",
"       \"Confidentiality in adolescent health care\", section on 'Potential threats to confidentiality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As many as 20 percent of adolescents may fail to fill prescriptions for STD treatment. Thus, single-dose, observed therapy may be preferable when available.",
"     </li>",
"     <li>",
"      Many adolescents may prefer to notify partners themselves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/24\">",
"       24",
"      </a>",
"      ]. However, this strategy means that a substantial number of partners are never notified. Because many adolescents have additional sexual contact with these partners, clinician counseling to reinforce the importance of notification may be useful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine assessment of sexual activity is an essential element of sexually transmitted disease (STD) -related care. However, a substantial proportion of adolescents are not evaluated for risk of acquiring STD during office visits. This failure applies to both established and new patients, as well as those who have demonstrated risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sexual history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sexual history (",
"    <a class=\"graphic graphic_table graphicRef61677 \" href=\"mobipreview.htm?36/21/37212\">",
"     table 1",
"    </a>",
"    ) should be straightforward and nonjudgmental, with appropriate counseling regarding risk-taking behaviors, as necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. An assurance of confidentiality is an important aspect of obtaining an accurate sexual history in adolescents; additional aspects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9866?source=see_link&amp;anchor=H15#H15\">",
"     \"Adolescent sexuality\", section on 'Health care provider issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many circumstances, a careful sexual history, a review of symptoms, and patient-obtained screening tests may replace routine pelvic examinations. Pelvic examinations are sources of substantial anxiety and discomfort for many adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Rather than a routine aspect of STD testing, genital examinations should be reserved for evaluation of specific symptoms or to complete evaluation of a specific differential diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An external genital examination is indicated for evaluation of genital lesions that may be caused by genital herpes, primary syphilis, or human papillomavirus (HPV). Menstrual irregularities (eg, amenorrhea not because of pregnancy, and prolonged or heavy vaginal bleeding) and abdominal and pelvic pain and tenderness may be important reasons for performing a speculum and bimanual pelvic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/33\">",
"     33",
"    </a>",
"    ]. A speculum examination is indicated for vaginal discharges that may be caused by a forgotten tampon, condom fragments, or other objects.",
"   </p>",
"   <p>",
"    Testing for STD using urine or other patient-obtained specimens is well accepted, and often preferred, by adolescents and offers a useful alternative to pelvic examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. As an example, adolescents preferred providing a urine sample to a vaginal swab obtained themselves or to a pelvic examination when all three were performed in a sample of 155 ethnically diverse patients referred for STD screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/37\">",
"     37",
"    </a>",
"    ]. However, a self-administered vaginal swab was the second choice for these patients over a pelvic examination, and other studies demonstrate a high degree of acceptability of self-obtained vaginal swabs among adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/36,41\">",
"     36,41",
"    </a>",
"    ]. Self-obtained vaginal specimens work at least as well as other specimen types in conjunction with nucleic acid amplification tests (NAAT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Although not FDA-approved, self-obtained vaginal swabs may be used for gonorrhea and chlamydia amplification testing but not for commonly used direct hybridization probe tests. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Nucleic acid amplification tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Papanicolaou (PAP) smear screening for cervical cancer and its precursors is another indication for performing a speculum pelvic examination. Cervical cancer screening is no longer recommended for adolescents &lt;21 years of age unless they are immune compromised (eg, HIV infection). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H22#H22\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Initial screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     STD CLINICAL PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A useful clinical approach to evaluating sexually transmitted diseases (STD) in all patients, including adolescents, is based upon the pattern of presenting symptoms and signs. These patterns can be useful initial guides for obtaining additional history and performing examination and laboratory testing. The symptoms and signs associated with STD in adolescents do not differ significantly from those in adults. Clinicians should bear in mind that asymptomatic or minimally symptomatic presentations are common",
"    <span class=\"nowrap\">",
"     occurrences.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Discharge syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral/vaginal",
"    discharge and dysuria are the hallmarks of gonorrhea, chlamydia, trichomoniasis, bacterial vaginosis, and candidiasis.",
"    <em>",
"     Mycoplasma genitalium",
"    </em>",
"    infections are increasingly recognized as causes of sexually transmitted discharge syndromes in adolescents and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/44\">",
"     44",
"    </a>",
"    ]. Genital herpes is sometimes associated with dysuria and a scant, mucoid urethral discharge, but nearly always in association with other genital lesions. These conditions are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Characteristics of the discharge, such as color (eg, clear, mucoid, yellow, green) are unreliable indicators of the etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genital ulcer syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, genital herpes is the most common cause of genital ulcer syndrome (GUS) among adolescents. Symptomatic genital herpes may be caused by herpes simplex virus (HSV) type 1 in addition to the more common HSV type 2, and the proportion of cases caused by the former appears to be increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/45\">",
"     45",
"    </a>",
"    ]. Speculation that this increase is because of increased prevalence of oral-genital contact among adolescents is unproven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary syphilis also is an important diagnostic consideration, especially in the setting of commercial sex work or crack cocaine use. Only 0.4 percent of females and 0.1 percent of males entering the Job Corps have a positive screening test for syphilis, suggesting that routine screening of asymptomatic, low-risk adolescents is not warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some adolescents may participate in high-risk sexual networks (eg, commercial sex work or crack cocaine use) that increase the possibility of syphilis as a cause of genital ulcers. More aggressive syphilis screening for these populations may be warranted. The clinical ascertainment of the etiology of GUS is unreliable because the features of infections associated with GUS overlap and because mixed infections occur in as many as 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, syphilis serologic testing should be included in the evaluation of GUS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common causes of GUS in the United States, and extremely rare in adolescents, include chancroid, lymphogranuloma venereum (LGV), and granuloma inguinale (",
"    <em>",
"     Calymmatobacterium granulomatis",
"    </em>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital ulcers are not always due to sexually transmitted organisms. Nonsexually transmitted vulvar ulcers (sometimes called Lipschutz ulcers, virginal ulcers, or aphthous ulcers) may occur in association with viral illness, Crohn's disease, vasculitis, and Behcet's disease (",
"    <a class=\"graphic graphic_picture graphicRef68284 \" href=\"mobipreview.htm?31/62/32739\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link&amp;anchor=H16#H16\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Vulvar ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID) is a common sequela of genital gonorrhea and chlamydia infections. Douching may increase the risk of developing PID, especially when performed frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/47\">",
"     47",
"    </a>",
"    ]. Regular douching is reported by 15 percent of adolescent women, with substantially higher proportions in some ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/48\">",
"     48",
"    </a>",
"    ]. PID can be a subclinical infection, and diagnosis may be difficult to make. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dermatologic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common STD with primarily dermatologic presentation is genital warts (condyloma acuminata) caused by HPV. HPV types 6 and 11 are the most common causes of genital warts. However, types 16, 18, and 52 (not typically associated with warts) are the most commonly identified HPV infections. Mixed infections with more than one HPV type may account for one-half or more of infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin rash is a common manifestation of secondary syphilis (",
"    <a class=\"graphic graphic_picture graphicRef68877 \" href=\"mobipreview.htm?9/3/9279\">",
"     picture 2",
"    </a>",
"    ). Condyloma lata are another dermatologic manifestation of secondary syphilis. They are characterized by large, raised, gray to white lesions, involving warm, moist areas such as mucous membranes in the mouth and perineum (",
"    <a class=\"graphic graphic_picture graphicRef66087 \" href=\"mobipreview.htm?42/15/43251\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63924 \" href=\"mobipreview.htm?26/12/26818\">",
"     picture 4",
"    </a>",
"    ). Secondary syphilis is an uncommon event in adolescents except in areas marked by high-risk sexual networks, commercial sex work, and cocaine use. When secondary syphilis is seen in adolescents, it typically reflects delayed care-seeking for primary syphilis lesions (chancres) (",
"    <a class=\"graphic graphic_picture graphicRef75291 \" href=\"mobipreview.htm?17/16/17664\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin rash is also a common manifestation of disseminated gonococcal infection (",
"    <a class=\"graphic graphic_picture graphicRef71303 \" href=\"mobipreview.htm?18/49/19219\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=see_link\">",
"     \"Disseminated gonococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediculosis pubis, caused by the crab louse (",
"    <a class=\"graphic graphic_picture graphicRef55191 \" href=\"mobipreview.htm?34/21/35158\">",
"     picture 7",
"    </a>",
"    ), and scabies, which may be transmitted by sexual activity, also present with dermatologic complaints. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1511?source=see_link\">",
"     \"Pediculosis pubis and pediculosis ciliaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=see_link\">",
"     \"Scabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SCREENING AND DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually active adolescent patients should be screened at least annually for gonorrhea and chlamydia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/4,22,49\">",
"     4,22,49",
"    </a>",
"    ]. In addition, patients who have particular risk factors (",
"    <a class=\"graphic graphic_table graphicRef73710 \" href=\"mobipreview.htm?18/16/18699\">",
"     table 2",
"    </a>",
"    ) should be screened annually for human immunodeficiency virus (HIV) and syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/22,49-51\">",
"     22,49-51",
"    </a>",
"    ]. Screening for HPV is not recommended because the results do not alter clinical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/31\">",
"     31",
"    </a>",
"    ]. HPV infections are not curable, and there is no evidence that screening influences risk of transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26229?source=see_link\">",
"     \"The life cycle, natural history, and immunology of human papillomaviruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2006 the Centers for Disease Control and Prevention (CDC) recommended that \"opt-out\" HIV testing be routinely offered to all patients aged 13 to 64 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/52\">",
"     52",
"    </a>",
"    ]. \"Opt-out\" testing involves informing the patient, orally or in writing, that HIV testing will be performed unless he or she declines. The Society for Adolescent Health and Medicine also supports offering HIV testing as part of routine care for sexually active adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/50\">",
"     50",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) recommends offering HIV testing at least once by 16 to 18 years in clinic settings where the prevalence of HIV is &gt;0.1 percent (information that can be obtained from the local health department or local HIV experts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/51\">",
"     51",
"    </a>",
"    ]. In clinic settings with lower HIV prevalence, the AAP encourages routine HIV testing for sexually active adolescents and those with other risk factors for HIV. The AAP recommends annual HIV testing for high risk adolescents (those who use intravenous drugs, exchange sex for money, have sex with multiple partners, or are men who have sex with men). Adolescents tested for other STD should be tested for HIV at the same visit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=see_link&amp;anchor=H12#H12\">",
"     \"Serologic screening for HIV infection\", section on 'Opt-out testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tests available for the detection of STD include light microscopy, culture, serology, Western blot, and several DNA probe or nucleic acid amplification methods. Each of these tests has an ongoing role in screening (ie, case-finding in at-risk, asymptomatic patients) or in clinical diagnosis. The CDC has published an excellent review of diagnostic methods for gonococcal and chlamydial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopy includes examination of vaginal fluid mixed with saline and with potassium hydroxide, and Gram stain. Self-obtained vaginal swabs perform comparably to clinician-obtained swabs and are well accepted by adolescent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/36,37,41\">",
"     36,37,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conditions for which microscopy are useful include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichomoniasis. The sensitivity of saline wet mount for diagnosis of trichomoniasis is considered to be 50 to 70 percent. Rapid tests for Trichomonas that have increased sensitivity compared with saline wet mount are available, but there is little published information about their use in adolescent patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link&amp;anchor=H7#H7\">",
"       \"Trichomonas vaginalis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial vaginosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link&amp;anchor=H5#H5\">",
"       \"Bacterial vaginosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vaginal candidiasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=see_link&amp;anchor=H7#H7\">",
"       \"Candida vulvovaginitis\", section on 'Office diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonococcal and non-gonococcal urethritis (in males). Gram stain (ie, finding of gram-negative intracellular diplococci) is both sensitive and specific (94, and 94 to 97 percent, respectively) for the diagnosis of gonococcal urethritis in symptomatic males [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. Non-gonococcal urethritis is diagnosed by finding five or more PMN per oil-immersion microscopic (1000x) field in the absence of gram-negative intracellular diplococci [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Performing Gram stain of cervical secretions in females is not recommended unless other diagnostic modes are unavailable. Gram stain of cervical secretions has a low sensitivity for diagnosing gonorrhea and a low specificity for diagnosing mucopurulent cervicitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture is used widely for the diagnosis of gonorrhea, chlamydia, and genital herpes. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    A relatively inexpensive self-contained culture system for",
"    <em>",
"     Trichomonas",
"    </em>",
"    is available. The culture system may be preferable to microscopy because it has greater sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/57\">",
"     57",
"    </a>",
"    ]. This test is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link&amp;anchor=H9#H9\">",
"     \"Trichomonas vaginalis\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests for herpes simplex virus (HSV) type 2 that identify circulating antibodies to specific herpes glycoproteins are available. The tests are highly sensitive and detect seroconversion within two to three weeks after initial infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H28#H28\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Serology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syphilis serology remains substantially dependent upon non-treponemal (eg, RPR or VDRL) screening tests followed by treponemal (eg, FTA) screening tests. Reasonably common causes of false-positive screening tests in adolescents include pregnancy, injection drug use, acute hepatitis B, and systemic lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serologic testing for HIV is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nucleic acid amplification tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification tests (NAAT) are highly sensitive tests for",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    and",
"    <em>",
"     C. trachomatis",
"    </em>",
"    that can be performed on genital specimens (urethral or cervical), as well as urine.",
"   </p>",
"   <p>",
"    The sensitivity of urine-based NAAT is decreased slightly compared with that of",
"    <span class=\"nowrap\">",
"     urethral/cervical",
"    </span>",
"    specimens but is comparable or superior to traditional cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"     53",
"    </a>",
"    ]. An NAAT with vaginal specimens (obtained by the patient or by a clinician) appears to be equivalent to that from cervical specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CDC suggests the following strategy for screening for",
"    <em>",
"     C. trachomatis",
"    </em>",
"    and",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women, cervical specimens assessed by an NAAT or culture if pelvic examination is performed; otherwise, an NAAT using a urine specimen is preferred",
"     </li>",
"     <li>",
"      For men, an NAAT or culture if endourethral swab specimens are obtained; otherwise, an NAAT using a urine specimen is preferred [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several NAAT are commercially available (",
"    <a class=\"graphic graphic_table graphicRef70321 \" href=\"mobipreview.htm?38/14/39147\">",
"     table 3",
"    </a>",
"    ). These tests differ somewhat in the method of nucleic acid amplification and in the targeted nucleic acid sequences but demonstrate comparable sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"     53",
"    </a>",
"    ]. Choice of one test over another for screening and diagnostic purposes is largely a matter of local laboratory preference.",
"   </p>",
"   <p>",
"    Tests based on nucleic acid hybridization also are commercially available for detection of",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    and",
"    <em>",
"     C. trachomatis",
"    </em>",
"    . These tests can be performed on a single specimen. However, additional tests are required for organism-specific results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urine screening for gonorrhea, chlamydia, or both using NAAT has been used successfully in difficult-to-reach adolescents (\"street kids\"), as well as in pediatric emergency departments and school-based settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. Screening in school-based settings was associated with significant reduction in chlamydia rates during a one-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost no clinical trials of sexually transmitted disease (STD) -related pharmaceuticals include participants younger than 16 years of age, and relatively few include 16- to 17-year-olds. Most data regarding safety and efficacy are extrapolated from late adolescents and young adults. Guidelines for the treatment of specific STD are regularly updated by the",
"    <a class=\"external\" href=\"file://www.cdc.gov/std/\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/31\">",
"     31",
"    </a>",
"    ]. (See individual topic reviews on sexually transmitted infections.)",
"   </p>",
"   <p>",
"    As many as 20 percent of adolescents may fail to fill prescriptions for STD treatment. Thus, single-dose, observed therapy may be preferable when available. Additional issues related to the treatment of STD that are particularly relevant in adolescent patients (eg, confidentiality, parental notification) are discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Unique issues in adolescents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Expedited partner therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expedited partner therapy (EPT) refers to the provision of appropriate single-dose antibiotics to patients with chlamydia or gonorrhea for delivery to partners. EPT is endorsed by the Society for Adolescent Health and Medicine and the American Academy of Pediatrics (AAP) as a strategy for ensuring partner treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/64\">",
"     64",
"    </a>",
"    ]. It is permissible in some states and prohibited in others. Additional information is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/std/ept/\">",
"     CDC",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Reinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high prevalence of",
"    <em>",
"     C. trachomatis",
"    </em>",
"    and",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    (reinfection rather than treatment failure) is observed in patients who were treated for STD in the preceding months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Women and men recently treated for chlamydia or gonorrhea should be retested approximately three months after treatment is completed and whenever they next seek medical care within the following 3 to 12 months (whether or not the patient thinks that the partner was treated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37689/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/21/1363?source=see_link\">",
"       \"Patient information: Teen sexuality (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/8/35973?source=see_link\">",
"       \"Patient information: Adolescent sexuality (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adolescence is a heterogeneous developmental period in terms of sexual behavior and risk of acquiring sexually transmitted diseases (STD). Behavioral and biologic factors contribute to the high levels of sexual activity and acquisition of STD in late adolescence; recurrent infection with sexually transmitted organisms is common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation and treatment of STD in adolescents raises a number of unique issues, including consent for diagnosis and treatment, adherence to therapy, confidentiality, parental notification, partner notification, and mandatory reporting of sexual activity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unique issues in adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful sexual history, review of symptoms, and patient-obtained screening tests may replace routine pelvic examinations in many cases. Testing for STD using urine or other patient-obtained specimens is well accepted by adolescents and offers a useful alternative to pelvic examinations. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Screening and diagnostic testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Speculum examinations are not routinely necessary in the evaluation for sexually transmitted infections in female adolescents. However, they are indicated in girls with menstrual irregularities, abdominal and pelvic pain and tenderness, vaginal discharge that may be caused by a foreign body (eg, forgotten tampon, condom fragment), and to screen for cervical cancer. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pattern of presenting symptoms and signs of STD can guide the need for additional information from the history, examination,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'STD clinical patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for the treatment of specific STD are regularly updated by the",
"      <a class=\"external\" href=\"file://www.cdc.gov/std/\">",
"       Centers for Disease Control and Prevention",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/1\">",
"      Forhan SE, Gottlieb SL, Sternberg MR, et al. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics 2009; 124:1505.",
"     </a>",
"    </li>",
"    <li>",
"     Sexually Transmitted Disease Surveillance, 2011. Centers for Disease Control and Prevention. file://www.cdc.gov/std/stats/ (Accessed on December 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/3\">",
"      Fortenberry JD, Brizendine EJ, Katz BP, et al. Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis. Sex Transm Dis 1999; 26:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/4\">",
"      Tu W, Batteiger BE, Wiehe S, et al. Time from first intercourse to first sexually transmitted infection diagnosis among adolescent women. Arch Pediatr Adolesc Med 2009; 163:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/5\">",
"      Kahn JA, Rosenthal SL, Succop PA, et al. Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection. Pediatrics 2002; 109:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/6\">",
"      Shew ML, Fortenberry JD, Miles P, Amortegui AJ. Interval between menarche and first sexual intercourse, related to risk of human papillomavirus infection. J Pediatr 1994; 125:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/7\">",
"      Burstein GR, Gaydos CA, Diener-West M, et al. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA 1998; 280:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/8\">",
"      Fortenberry JD. Adolescent substance use and sexually transmitted diseases risk: a review. J Adolesc Health 1995; 16:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/9\">",
"      Leigh BC. Alcohol and condom use: a meta-analysis of event-level studies. Sex Transm Dis 2002; 29:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/10\">",
"      Niccolai LM, Ethier KA, Kershaw TS, et al. New sex partner acquisition and sexually transmitted disease risk among adolescent females. J Adolesc Health 2004; 34:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Trends in sexual risk behaviors among high school students--United States, 1991-2001. MMWR Morb Mortal Wkly Rep 2002; 51:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/12\">",
"      Moscicki AB, Ma Y, Holland C, Vermund SH. Cervical ectopy in adolescent girls with and without human immunodeficiency virus infection. J Infect Dis 2001; 183:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/13\">",
"      McGrath JW, Strasburger VC, Cushing AH. Secretory IgA in cervical mucus. J Adolesc Health 1994; 15:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/14\">",
"      Ellen JM, Lammel CJ, Shafer MA, et al. Cervical secretory immunoglobulin A in adolescent girls. J Adolesc Health 1999; 25:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/15\">",
"      Ford CA, Best D, Miller WC. The pediatric forum: confidentiality and adolescents' willingness to consent to sexually transmitted disease testing. Arch Pediatr Adolesc Med 2001; 155:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/16\">",
"      Thrall JS, McCloskey L, Ettner SL, et al. Confidentiality and adolescents' use of providers for health information and for pelvic examinations. Arch Pediatr Adolesc Med 2000; 154:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/17\">",
"      Leitenberg H, Saltzman H. A statewide survey of age at first intercourse for adolescent females and age of their male partners: relation to other risk behaviors and statutory rape implications. Arch Sex Behav 2000; 29:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/18\">",
"      Silverman JG, Raj A, Mucci LA, Hathaway JE. Dating violence against adolescent girls and associated substance use, unhealthy weight control, sexual risk behavior, pregnancy, and suicidality. JAMA 2001; 286:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/19\">",
"      Wilson KM, Klein JD. Opportunities for appropriate care: health care and contraceptive use among adolescents reporting unwanted sexual intercourse. Arch Pediatr Adolesc Med 2002; 156:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/20\">",
"      Shrier LA, Pierce JD, Emans SJ, DuRant RH. Gender differences in risk behaviors associated with forced or pressured sex. Arch Pediatr Adolesc Med 1998; 152:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/21\">",
"      Fortenberry JD. Health care seeking behaviors related to sexually transmitted diseases among adolescents. Am J Public Health 1997; 87:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/22\">",
"      American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion #301: Sexually transmitted diseases in adolescents. Obstet Gynecol 2004; 104:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/23\">",
"      Conard LA, Fortenberry JD, Blythe MJ, Orr DP. Pharmacists' attitudes toward and practices with adolescents. Arch Pediatr Adolesc Med 2003; 157:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/24\">",
"      Oh MK, Boker JR, Genuardi FJ, et al. Sexual contact tracing outcome in adolescent chlamydial and gonococcal cervicitis cases. J Adolesc Health 1996; 18:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/25\">",
"      Fortenberry JD, Brizendine EJ, Katz BP, Orr DP. Post-treatment sexual and prevention behaviours of adolescents with sexually transmitted infections. Sex Transm Infect 2002; 78:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/26\">",
"      Fortenberry JD, Brizendine EJ, Katz BP, Orr DP. The role of self-efficacy and relationship quality in partner notification by adolescents with sexually transmitted infections. Arch Pediatr Adolesc Med 2002; 156:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/27\">",
"      Niccolai LM, Ickovics JR, Zeller K, et al. Knowledge of sex partner treatment for past bacterial STI and risk of current STI. Sex Transm Infect 2005; 81:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/28\">",
"      Halpern-Felsher BL, Ozer EM, Millstein SG, et al. Preventive services in a health maintenance organization: how well do pediatricians screen and educate adolescent patients? Arch Pediatr Adolesc Med 2000; 154:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/29\">",
"      Ellen JM, Lane MA, McCright J. Are adolescents being screened for sexually transmitted diseases? A study of low income African American adolescents in San Francisco. Sex Transm Infect 2000; 76:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/30\">",
"      Torkko KC, Gershman K, Crane LA, et al. Testing for Chlamydia and sexual history taking in adolescent females: results from a statewide survey of Colorado primary care providers. Pediatrics 2000; 106:E32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/31\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/32\">",
"      Larsen SB, Kragstrup J. Experiences of the first pelvic examination in a random samples of Danish teenagers. Acta Obstet Gynecol Scand 1995; 74:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/33\">",
"      Braverman PK, Breech L, Committee on Adolescence. American Academy of Pediatrics. Clinical report--gynecologic examination for adolescents in the pediatric office setting. Pediatrics 2010; 126:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/34\">",
"      Shafer MA, Pantell RH, Schachter J. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Arch Pediatr Adolesc Med 1999; 153:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/35\">",
"      Cohen DA, Nsuami M, Martin DH, Farley TA. Repeated school-based screening for sexually transmitted diseases: a feasible strategy for reaching adolescents. Pediatrics 1999; 104:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/36\">",
"      Wiesenfeld HC, Lowry DL, Heine RP, et al. Self-collection of vaginal swabs for the detection of Chlamydia, gonorrhea, and trichomoniasis: opportunity to encourage sexually transmitted disease testing among adolescents. Sex Transm Dis 2001; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/37\">",
"      Serlin M, Shafer MA, Tebb K, et al. What sexually transmitted disease screening method does the adolescent prefer? Adolescents' attitudes toward first-void urine, self-collected vaginal swab, and pelvic examination. Arch Pediatr Adolesc Med 2002; 156:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/38\">",
"      Tebb KP, Paukku MH, Pai-Dhungat MR, et al. Home STI testing: the adolescent female's opinion. J Adolesc Health 2004; 35:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/39\">",
"      Schoeman SA, Stewart CM, Booth RA, et al. Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ 2012; 345:e8013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/40\">",
"      Stewart CM, Schoeman SA, Booth RA, et al. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. BMJ 2012; 345:e8107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/41\">",
"      Smith K, Harrington K, Wingood G, et al. Self-obtained vaginal swabs for diagnosis of treatable sexually transmitted diseases in adolescent girls. Arch Pediatr Adolesc Med 2001; 155:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/42\">",
"      Hobbs MM, van der Pol B, Totten P, et al. From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis 2008; 35:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/43\">",
"      Fang J, Husman C, DeSilva L, et al. Evaluation of self-collected vaginal swab, first void urine, and endocervical swab specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in adolescent females. J Pediatr Adolesc Gynecol 2008; 21:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/44\">",
"      Tosh AK, Van Der Pol B, Fortenberry JD, et al. Mycoplasma genitalium among adolescent women and their partners. J Adolesc Health 2007; 40:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/45\">",
"      Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/46\">",
"      DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997; 25:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/47\">",
"      Ness RB, Soper DE, Holley RL, et al. Douching and endometritis: results from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis 2001; 28:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/48\">",
"      Merchant JS, Oh K, Klerman LV. Douching: a problem for adolescent girls and young women. Arch Pediatr Adolesc Med 1999; 153:834.",
"     </a>",
"    </li>",
"    <li>",
"     Recommendations for preventive pediatric health care. Pediatrics 2007; 120:1376. practice.aap.org/content.aspx?aid=1599 (Accessed on November 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/50\">",
"      D'Angelo LJ, Samples C, Rogers AS, et al. HIV infection and AIDS in adolescents: an update of the position of the Society for Adolescent Medicine. J Adolesc Health 2006; 38:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/51\">",
"      Committee on Pediatric AIDS, Emmanuel PJ, Martinez J. Adolescents and HIV infection: the pediatrician's role in promoting routine testing. Pediatrics 2011; 128:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/52\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/53\">",
"      Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/54\">",
"      Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 1996; 72:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/55\">",
"      Goodhart ME, Ogden J, Zaidi AA, Kraus SJ. Factors affecting the performance of smear and culture tests for the detection of Neisseria gonorrhoeae. Sex Transm Dis 1982; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/56\">",
"      Bornstein J, Lakovsky Y, Lavi I, et al. The classic approach to diagnosis of vulvovaginitis: a critical analysis. Infect Dis Obstet Gynecol 2001; 9:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/57\">",
"      Hook EW 3rd. Trichomonas vaginalis--no longer a minor STD. Sex Transm Dis 1999; 26:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/58\">",
"      Hook EW 3rd, Ching SF, Stephens J, et al. Diagnosis of Neisseria gonorrhoeae infections in women by using the ligase chain reaction on patient-obtained vaginal swabs. J Clin Microbiol 1997; 35:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/59\">",
"      Auerswald CL, Sugano E, Ellen JM, Klausner JD. Street-based STD testing and treatment of homeless youth are feasible, acceptable and effective. J Adolesc Health 2006; 38:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/60\">",
"      Monroe KW, Weiss HL, Jones M, Hook EW 3rd. Acceptability of urine screening for Neisseria gonorrheae and Chlamydia trachomatis in adolescents at an urban emergency department. Sex Transm Dis 2003; 30:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/61\">",
"      Aldeen T, Haghdoost A, Hay P. Urine based screening for asymptomatic/undiagnosed genital chlamydial infection in young people visiting the accident and emergency department is feasible, acceptable, and can be epidemiologically helpful. Sex Transm Infect 2003; 79:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/62\">",
"      Rietmeijer CA, Bull SS, Ortiz CG, et al. Patterns of general health care and STD services use among high-risk youth in Denver participating in community-based urine chlamydia screening. Sex Transm Dis 1998; 25:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/63\">",
"      Cohen DA, Nsuami M, Etame RB, et al. A school-based Chlamydia control program using DNA amplification technology. Pediatrics 1998; 101:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/64\">",
"      Burstein GR, Eliscu A, Ford K, et al. Expedited partner therapy for adolescents diagnosed with chlamydia or gonorrhea: a position paper of the Society for Adolescent Medicine. J Adolesc Health 2009; 45:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/65\">",
"      Kjaer HO, Dimcevski G, Hoff G, et al. Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 weeks' prospective follow up study. Sex Transm Infect 2000; 76:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/66\">",
"      Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001; 28:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/67\">",
"      Oh MK, Cloud GA, Fleenor M, et al. Risk for gonococcal and chlamydial cervicitis in adolescent females: incidence and recurrence in a prospective cohort study. J Adolesc Health 1996; 18:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37689/abstract/68\">",
"      Thomas JC, Weiner DH, Schoenbach VJ, Earp JA. Frequent re-infection in a community with hyperendemic gonorrhoea and chlamydia: appropriate clinical actions. Int J STD AIDS 2000; 11:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 115 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37689=[""].join("\n");
var outline_f36_51_37689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Behavioral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UNIQUE ISSUES IN ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sexual history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      STD CLINICAL PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Discharge syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genital ulcer syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dermatologic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SCREENING AND DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nucleic acid amplification tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Expedited partner therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Reinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/115|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/62/32739\" title=\"picture 1\">",
"      Vulvar ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/3/9279\" title=\"picture 2\">",
"      Rash in secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/15/43251\" title=\"picture 3\">",
"      Mucous patch secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/12/26818\" title=\"picture 4\">",
"      Condyloma lata syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/16/17664\" title=\"picture 5\">",
"      Penile chancre in syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/49/19219\" title=\"picture 6\">",
"      Gonococcal skin lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35158\" title=\"picture 7\">",
"      Pediculosis pubis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/21/37212\" title=\"table 1\">",
"      Five Ps of sexual history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/16/18699\" title=\"table 2\">",
"      Annual HIV and syphilis screening for adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/14/39147\" title=\"table 3\">",
"      GC chlamydia nucleic acid tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/8/35973?source=related_link\">",
"      Patient information: Adolescent sexuality (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/21/1363?source=related_link\">",
"      Patient information: Teen sexuality (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1511?source=related_link\">",
"      Pediculosis pubis and pediculosis ciliaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/31/10744?source=related_link\">",
"      Pregnancy in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/44/1737?source=related_link\">",
"      The adolescent with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26229?source=related_link\">",
"      The life cycle, natural history, and immunology of human papillomaviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_51_37690="Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management";
var content_f36_51_37690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Francis J Hornicek, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/51/37690/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/51/37690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcoma is the most common primary malignant tumor of bone. Osteosarcomas are characterized by the production of osteoid tissue or immature bone by the malignant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Osteosarcomas are uncommon tumors compared to carcinomas, with approximately 900 cases diagnosed each year in the United States, mainly in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/4\">",
"     4",
"    </a>",
"    ]. Among 15 to 29 year olds, bone tumors account for 3 percent of all tumors, and osteosarcoma accounts for about one-half of these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/5\">",
"     5",
"    </a>",
"    ]. Most osteosarcomas present as high-grade tumors and most are located around the anatomic regions of high growth rate.",
"   </p>",
"   <p>",
"    The survival of patients with malignant bone sarcomas has improved dramatically over the past 30 years, largely as a result of chemotherapeutic advances. Before the era of effective chemotherapy, 80 to 90 percent of patients with osteosarcoma developed metastatic disease despite achieving local control from surgery and died of their disease. It was surmised (and subsequently demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/6\">",
"     6",
"    </a>",
"    ]) that the majority of these patients had subclinical metastatic disease that was present at the time of diagnosis, even in the absence of overt metastases.",
"   </p>",
"   <p>",
"    In osteosarcoma, chemotherapy can successfully eradicate microscopic deposits in the majority of cases if initiated at a time when disease burden is low (ie, following resection of the primary tumor). As a result, all patients with intermediate- or high-grade osteosarcoma receive chemotherapy, although the optimal timing (ie, preoperative or postoperative) is controversial (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Adjuvant therapy'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/7\">",
"     7",
"    </a>",
"    ]. Low-grade osteosarcomas, such as parosteal osteosarcomas, are not treated routinely with chemotherapy because the risk of metastatic spread is low.",
"   </p>",
"   <p>",
"    With modern therapy, approximately two-thirds of patients with non-metastatic extremity osteosarcoma will be long-term survivors, up to 50 percent of those with limited pulmonary metastases may be cured of their disease, and long-term relapse-free survival can be expected in about 25 percent of those who present with metastatic disease overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/8-12\">",
"     8-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical management has evolved in parallel with the emergence of effective chemotherapy. Although complete extirpation of the tumor remains the primary objective, the nature and scope of the approach taken to accomplish this goal has changed, with an emphasis on more conservative surgery in order to maintain function. Functional outcome depends not only on the extent of resection and the amount of muscle that is removed, but also the quality of the reconstruction and its associated complications. Limb-sparing surgery rather than amputation is now possible in the majority of patients, particularly when preoperative (neoadjuvant) chemotherapy is used.",
"   </p>",
"   <p>",
"    Here we will discuss the principles of surgical management for primary bone sarcomas. Although the focus of this topic review will be on osteosarcoma, most of the same surgical principles apply to other bone sarcomas as well. Intermediate or high-grade fibrosarcoma of bone (previously referred to as malignant fibrous histiocytoma) is treated in a similar manner as osteosarcoma. Other bone sarcomas, such as leiomyosarcoma and chondrosarcoma, may be managed with a slightly different approach because of differences in their responsiveness to chemotherapy and radiation therapy. As an example, neoadjuvant chemotherapy is usually not considered routine for chondrosarcomas, because they are relatively chemoresistant. Leiomyosarcoma of bone has typically been treated in a similar manner to that of the leiomyosarcoma in soft tissues. In contrast, Ewing sarcoma is usually approached initially with systemic chemotherapy due to its chemosensitivity. Radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may be used to aid in local control for Ewing sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"     \"Chondrosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery can be a component of management of metastatic disease both at initial presentation, and at the time of recurrence, is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H19#H19\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Surgery and radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the preoperative evaluation is to establish the tissue diagnosis, evaluate disease extent, and assess the feasibility of a limb-sparing approach. Clinical staging includes all of the data obtained prior to definitive therapy, including the results of imaging, physical examination, laboratory studies, and tissue biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough history and physical examination that evaluates all systems is necessary prior to definitive treatment. However, physical examination should focus particularly on the involved bone or joint. The regional lymph nodes (although they are a rare site for metastases), other bones (sometimes synchronous but may be site for distant disease), and lungs (the most common metastatic site) are sites for disease dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are nearly always a good way to begin to evaluate a bone lesion, as they provide data that often cannot be replicated even with MRI or CT. Nonetheless, although plain radiographs can often predict the probable histology of a potentially malignant bone lesion, the definition of tumor size and local intraosseous and extraosseous extent is most accurately achieved by magnetic resonance imaging (MRI). The entire involved bone should be imaged to avoid missing skip metastases (ie, medullary disease within the same bone, but not in direct contiguity with the primary lesion) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59394 \" href=\"mobipreview.htm?2/47/2801\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CT scans are best suited to evaluate the thorax for metastatic disease, which is essential because approximately 80 percent of metastatic lesions in osteosarcoma occur in the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The most common metastatic site for all bone sarcomas is pulmonary. Thin-section imaging of the chest using high-resolution helical CT is the preferred modality, detecting approximately 20 to 25 percent more nodules than conventional CT, and the reliable detection of nodules as small as 2 to 3 mm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link&amp;anchor=H12#H12\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radionuclide bone scanning with technetium is the preferred method for evaluating the entire skeleton for the presence of multiple lesions and help in identifying skip metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/15\">",
"     15",
"    </a>",
"    ]. Although positron emission tomography (PET) scans may have greater utility for assessing the response of the primary tumor to neoadjuvant chemotherapy, at least one study suggests it is inferior to radionuclide bone scanning for the detection of osseous metastases from osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/16\">",
"     16",
"    </a>",
"    ] and to spiral (helical) CT for detecting pulmonary metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/17\">",
"     17",
"    </a>",
"    ]. Nevertheless, guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest a PET scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone scan in the workup of a suspected osteosarcoma, and imaging guidelines from the Children&rsquo;s Oncology Group Bone Tumor Committee for both osteosarcoma and Ewing sarcoma recommend radionuclide bone scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET scan for whole body staging. This subject is addressed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H15#H15\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of the tumor completes the staging process. As with soft tissue sarcomas, the biopsy must be carefully planned to ensure that adequate tissue is obtained for diagnosis without compromising the opportunity for limb salvage. Biopsies should take place after the completion of the staging studies, and the surgeon, radiologist, and pathologist should review these studies in detail so that each member of the team is fully appraised of the diagnostic considerations.",
"   </p>",
"   <p>",
"    Either a core needle or open biopsy may be performed as long as adequate tissue is obtained. For CT-guided core biopsies, multiple cores of tissue should be obtained for frozen section (to ensure that adequate tissue has been obtained), permanent hematoxylin and eosin (H&amp;E) stained sections, microbial culture (in case the diagnosis should turn out to be osteomyelitis), and one core is reserved for special stains or cytogenetic studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link&amp;anchor=H21#H21\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\", section on 'Specimen handling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although fine needle aspiration biopsy under radiologic guidance may obviate the need for open biopsy, the risk of a nondiagnostic or nonrepresentative sample must be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/18\">",
"     18",
"    </a>",
"    ]. In one report of 359 patients with musculoskeletal lesions, the accuracy rates of CT-guided biopsies and fine needle aspirates were 74 and 63 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link&amp;anchor=H11#H11\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\", section on 'Planning the biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an open biopsy is performed, the incision should be placed in accordance with the planned surgical resection; the primary tumor and the entire biopsy tract should be resected en bloc. Meticulous hemostasis and the judicious use of a drain are important to avoid the spread of hematoma-containing tumor cells. If a soft tissue mass is not present, or material is nondiagnostic, a bone defect may be required to obtain tissue. If so, it should be a small, oval defect, and a polymethylmethacrylate plug may be used to close the hole in order to minimize hematoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link&amp;anchor=H13#H13\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\", section on 'Operative biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tumor staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system used primarily for bone sarcomas was developed by Enneking et al at the University of Florida and based upon a retrospective review of cases of primary malignant tumors of bone treated by primary surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This system characterizes nonmetastatic malignant bone tumors by grade (low grade [stage I] versus high grade [stage II]), and further subdivides these stages according to the local anatomic extent (intracompartmental [A] versus extracompartmental [B]). The compartmental status is determined by whether the tumor extends through the cortex of the involved bone. Patients with distant metastases are categorized as stage III.",
"   </p>",
"   <p>",
"    The American Joint Committee on Cancer (AJCC) adopted a similar staging system in its 1997 fifth edition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/3\">",
"     3",
"    </a>",
"    ], but this was modified in 2002, with additional minor refinements in the latest 2010 edition (",
"    <a class=\"graphic graphic_table graphicRef62124 \" href=\"mobipreview.htm?25/43/26301\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/22\">",
"     22",
"    </a>",
"    ]. The TNM classification is not widely used for primary bone tumors, particularly for Ewing sarcoma, since it does not take into account several important clinicopathologic features such as primary tumor site, patient age, and histology. The staging classification used for Ewing sarcoma is complex and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary bone sarcomas are classified according to their cytologic features and cellular products (eg, osteoid) (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"     table 2",
"    </a>",
"    ). The different types of osteosarcomas are briefly described here. For other sarcomas of bone (eg, chondrosarcoma), subtypes exist as well, based upon the histology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"     \"Chondrosarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link&amp;anchor=H15#H15\">",
"     \"Chordoma and chondrosarcoma of the skull base\", section on 'Chondrosarcoma'",
"    </a>",
"    .) The histologic appearance of the Ewing sarcoma family of tumors is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\", section on 'Histogenesis and histology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of a primary bone malignancy should be rendered only in the setting of radiologic studies, including plain films and MRI or CT of the primary lesion. While radiologic or histologic findings may not be specific by themselves, a histologic diagnosis in the context of consistent radiographic findings secures the diagnosis with much greater certainty.",
"   </p>",
"   <p>",
"    The histologic diagnosis of an osteosarcoma depends upon the presence of a malignant sarcomatous stroma associated with the production of tumor osteoid or tumor bone. Osteosarcomas are thought to arise from a mesenchymal stem cell that is capable of differentiating towards fibrous tissue, cartilage, or bone. As a result, they share many features with chondrosarcomas and fibrosarcomas of bone. However, chondrosarcomas and fibrosarcomas of bone are distinguished by their lack of osteoid substance, which is required for the diagnosis of osteosarcoma (",
"    <a class=\"graphic graphic_table graphicRef70051 \" href=\"mobipreview.htm?13/44/14029\">",
"     table 3",
"    </a>",
"    ). Of note, the degree of osteoid production in osteosarcomas may be limited; because of this and variability in tumor morphology, electron microscopy may be required for histologic confirmation.",
"   </p>",
"   <p>",
"    The largest group of osteosarcomas are conventional (intramedullary high grade) osteosarcomas, which account for approximately 90 percent of all osteosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/23\">",
"     23",
"    </a>",
"    ]. These tumors usually involve the metaphysis of long bones in adolescents and young adults (",
"    <a class=\"graphic graphic_figure graphicRef76662 \" href=\"mobipreview.htm?22/53/23391\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Conventional osteosarcomas can be classified as osteoblastic, chondroblastic, or fibroblastic, depending upon the predominant cellular component (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"     table 2",
"    </a>",
"    ); all are managed similarly if they are of the same grade:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoblastic osteosarcoma, which accounts for 50 percent of cases, is characterized by abundant osteoid production, which forms a fine or coarse lacelike pattern around the tumor cells; massive amounts may result in distortion of the malignant stromal cells. Some tumors contain thick trabeculae of osteoid that form an irregular anastomosing network. The amount of mineralization is variable.",
"     </li>",
"     <li>",
"      Fibroblastic osteosarcomas are predominantly composed of a high-grade spindle cell stroma that contains only focal osteoid production. More pleomorphic tumors may resemble malignant fibrous histiocytoma, but the distinction can be made by the identification of osteoid.",
"     </li>",
"     <li>",
"      In chondroblastic osteosarcomas, cartilaginous matrix production may be evident throughout most of the tumor or only in certain locations, underscoring the heterogeneity of these tumors. While some chondroblastic osteosarcomas tend to be lower grade, the chondroid areas may contain cytologically atypical cells that are characteristic of higher grade tumors. These chondroblastic foci are admixed with malignant spindle cells that produce osteoid trabecula.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the three categories of conventional osteosarcoma, there are several variants (ie, telangiectatic, small cell, multifocal, and the malignant fibrous histiocytoma [fibrosarcoma] subtypes) that were originally thought to carry a worse prognosis. However, with modern aggressive therapy, they behave in general like conventional osteosarcomas and are treated similarly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small cell osteosarcoma is noteworthy for the confusion that may arise in distinguishing it from other \"small round blue cell tumors\" such as Ewing sarcoma by conventional light microscopy of H&amp;E stained sections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/24\">",
"       24",
"      </a>",
"      ]. Immunohistochemical staining, cytogenetics, and molecular genetic studies may be required to establish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"       \"Treatment of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Telangiectatic osteosarcoma has a purely lytic appearance on plain radiographs, and there is a high rate of pathologic fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/25\">",
"       25",
"      </a>",
"      ]. Grossly, these tumors appear like a \"multicystic bag of blood\"; a solid mass of tumor is usually absent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/23\">",
"       23",
"      </a>",
"      ]. Telangiectatic osteosarcomas have overlapping features with aneurysmal bone cysts and giant cell tumors. However, the cells are highly pleomorphic, unlike the benign appearance of the aneurysmal bone cyst. Because they often contain minimal osteoid and numerous multinucleated giant cells, they may be mistaken for a giant cell tumor. Although once thought to carry a poorer prognosis that conventional osteosarcomas, more recent series indicate similar survival with multimodality therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5658?source=see_link\">",
"       \"Giant cell tumor of bone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of benign bone tumors in children and adolescents\", section on 'Aneurysmal bone cyst'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibrosarcoma of bone (previously referred to as malignant fibrous histiocytoma of bone) has an appearance similar to osteosarcoma, but without osteoid production. Although these tumors tend to have a lower rate of tumor necrosis following induction chemotherapy, long-term survival rates for intermediate and high-grade fibrosarcomas of bone are similar to conventional osteosarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/27\">",
"       27",
"      </a>",
"      ], with the possible exception of spine primaries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      With very careful examination, occasionally osteoid will be found in rare sections of tumor, suggesting that this subtype of primary bone tumor may represent an undifferentiated version of a more classic osteosarcoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227072#H12227072\">",
"       \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Histopathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these variants, surface or juxtacortical osteosarcomas differ as a group with respect to prognosis and therapy. These osteosarcomas include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parosteal osteosarcoma is a low-grade osteosarcoma",
"     </li>",
"     <li>",
"      Periosteal osteosarcomas are usually chondroblastic intermediate grade tumors (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68702 \" href=\"mobipreview.htm?32/49/33552\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      There are rare high-grade surface osteosarcomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the surface osteosarcomas, surgery alone may be curative, particularly for tumors that are low-grade and do not enter the marrow cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, at least some data support the benefit of adjuvant chemotherapy in periosteal and high-grade surface osteosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/31\">",
"     31",
"    </a>",
"    ]. Given the rarity of this diagnosis, it is worthwhile obtaining a second opinion regarding the pathology and radiology for such tumors at expert centers.",
"   </p>",
"   <p>",
"    Because of the rarity of osteosarcoma in adults, other cancers should be considered in the differential diagnosis, such as primary lymphoma of bone and metastatic carcinoma, in addition to the primary bone tumors discussed above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32599?source=see_link\">",
"     \"Primary lymphoma of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Besides osteosarcomas, fibrosarcomas, and chondrosarcomas, other less common primary bone tumors include primitive neuroectodermal",
"    <span class=\"nowrap\">",
"     tumor/Ewing",
"    </span>",
"    sarcoma, chordomas, angiosarcomas (a subtype with a particularly high rate of metastatic disease at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/34\">",
"     34",
"    </a>",
"    ]), and a variety of other rare tumor types (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"     table 2",
"    </a>",
"    ). Histologic characteristics of the Ewing sarcoma family of tumors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\", section on 'Histogenesis and histology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT OF THE PRIMARY TUMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the favorable response of osteosarcomas to chemotherapy (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    below), surgery is a necessary component of curative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/35\">",
"     35",
"    </a>",
"    ]. The specific surgical procedure is dictated by the location and extent of the primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/36\">",
"     36",
"    </a>",
"    ]. Axial tumors tend to do worse probably because they are larger when discovered and more difficult to resect. Although all patients with extremity sarcomas are candidates for amputation, emphasis on functional outcome has focused efforts on limb-sparing procedures. However, not all patients are candidates for more conservative surgery (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Patient selection'",
"    </a>",
"    below). In order to avoid sacrificing oncologic outcome, tumor control must be the primary therapeutic concern, and functional outcome a secondary goal. One of the most important tasks of the preoperative evaluation is to assess the feasibility of performing a limb-salvage procedure based upon the clinical presentation and disease extent (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Preoperative evaluation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Types of resections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone resections fall into one of three categories, depending upon the anatomic site and the extent of the involved bone that needs to be excised. Because most bone sarcomas arise in the metaphysis of the long bones near a joint (",
"    <a class=\"graphic graphic_figure graphicRef50795 \" href=\"mobipreview.htm?13/34/13864\">",
"     figure 2",
"    </a>",
"    ), the majority of resections, for tumors in the lower extremity, include both the segment of tumor-bearing bone and the adjacent joint (osteoarticular resection). Most often, the incision is performed through the joint (intraarticular resection); however, when the tumor extends along the joint capsule or ligamentous structures or invades the joint, the entire joint can be resected (extraarticular resection) to avoid cutting through tumor.",
"   </p>",
"   <p>",
"    Less frequently, tumor arises within the diaphysis or shaft region of a long bone, and the bone alone is resected (an intercalary resection). Uncommonly, extensive involvement along the length of the bone precludes adequate resection and reconstruction without sacrificing the entire bone, and a whole bone resection, including both proximal and distal joints, is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Resection margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in selecting the type of operation is the ability to attain a negative margin of resection with the planned surgical procedure. The quality of the tissue forming the margin is as important as the distance between tumor and uninvolved tissue. The Musculoskeletal Tumor Society recognizes a wide local excision either by amputation or a limb-sparing procedure as the recommended surgical approach to bone sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/37\">",
"     37",
"    </a>",
"    ]. The wide local excision removes the primary tumor en bloc along with its reactive zone and a cuff of normal tissue in all planes. However, in many cases, particularly for tumors involving the spine, wide local excision cannot be accomplished easily. An \"intralesional\" surgical resection margin is more frequently obtained during a procedure that removes the tumor in a piecemeal fashion or by curettage, while a \"marginal\" resection margin refers to a situation where the pseudocapsule and reactive zone surrounding the tumor form the surgical margin. These operations may result in residual tumor cells being left behind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extremity lesions: limb-sparing procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;For lesions involving either the upper or lower extremity, limb salvage can improve functional outcome without sacrificing local disease control as long as complete tumor resection is anatomically possible and adjuvant chemotherapy is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/12,38,39\">",
"     12,38,39",
"    </a>",
"    ]. Although the functional results are generally better, the available data do not support the position that quality of life or long-term psychosocial outcome is substantially superior after limb salvage than after amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. There is, however, a higher complication rate in patients who undergo limb salvage as compared to amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/40,45\">",
"     40,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the increasing numbers of limb salvage procedures, there are no randomized prospective studies that prove its oncologic safety compared to amputation. However, retrospective series with long-term follow-up of patients with osteosarcoma who undergo amputation or limb salvage do not show a difference in overall or disease-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/46\">",
"     46",
"    </a>",
"    ]. Nevertheless, appropriate patient selection is critical (see below). If there is any doubt that a wide local excision can be accomplished, amputation, the oncologic \"gold standard\", is the indicated procedure in order to avoid local recurrence, which is invariably followed by metastatic tumor spread and diminished survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to amputation, limb salvage procedures are usually associated with narrower surgical margins, which can increase the likelihood of a local failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. The degree of chemotherapy-induced tumor necrosis and surgical margin status are the important prognostic factors for local control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. For patients undergoing neoadjuvant chemotherapy in order to increase the feasibility of a limb sparing procedure, it is unclear whether the reduction in surgical margins afforded by a favorable antitumor response increases the likelihood of a local recurrence. The available data are contradictory. Several multicenter series suggest an increased risk of local recurrence, even in patients with a good response to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/49,51,53\">",
"     49,51,53",
"    </a>",
"    ], while other single institution studies indicate similar local recurrence rates for limb-sparing and amputation procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/48,52\">",
"     48,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor location and extent are the most important determinants of the feasibility of limb-sparing surgery. Among the contraindications for limb-sparing surgery are nerve",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vessel encasement by tumor, the presence of a large biopsy-related hematoma, and possibly the presence of a pathologic fracture.",
"   </p>",
"   <p>",
"    A pathologic fracture is present at diagnosis or occurs during the course of treatment in 5 to 10 percent of patients with osteosarcoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86777 \" href=\"mobipreview.htm?21/33/22036\">",
"     image 3",
"    </a>",
"    ). Historically a pathologic fracture was considered an indication for immediate amputation because of the theoretical presence of tumor cells within the hematoma, and a greater risk of both local recurrence and shorter survival with limb-sparing procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. However, more recent studies have suggested that limb salvage is possible with an acceptable rate of local control:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multi-institutional series from the Musculoskeletal Tumor Society compared outcomes for 52 patients with osteosarcoma and a pathologic fracture versus those in 55 concurrently treated patients, matched for age and tumor location, who had an osteosarcoma without a pathologic fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/54\">",
"       54",
"      </a>",
"      ]. Overall, both five-year overall (55 versus 77 percent) and local recurrence-free survival rates (75 versus 96 percent) were significantly poorer for those presenting with a pathologic fracture. However, there were no significant differences in outcome when limb salvage was compared to amputation in patients with a pathologic fracture: 11 of 30 patients managed with limb salvage (37 percent) versus 10 of 22 who underwent amputation (45 percent, p = 0.05) died of their disease.",
"     </li>",
"     <li>",
"      A single-institution retrospective review compared outcomes of 31 patients with high-grade osteosarcoma who presented with a pathologic fracture versus 201 patients without a pathologic fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/59\">",
"       59",
"      </a>",
"      ]. In the pathologic fracture group, 19 patients had limb salvage surgery (61 percent), while 12 underwent an amputation; limb salvage surgery was performed in 86 percent of the non-fracture group. Five-year overall survival was significantly worse for patients presenting with a pathologic fracture (41 versus 60 percent), but there was no difference in local recurrence rate after limb-sparing surgery in the pathologic fracture versus no-fracture group (10 versus 8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reports indicate that healing of pathological fractures during neoadjuvant chemotherapy may permit limb-salvage surgery to be undertaken safely, as long as wide surgical margins can be achieved. In many of these series, the majority of patients were treated with limb-sparing approaches, and the presence of a pathologic fracture did not constitute a negative prognostic factor for either local recurrence or survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/55,60\">",
"     55,60",
"    </a>",
"    ]. Despite these data, many investigators still consider a pathologic fracture to be a relative rather than an absolute contraindication to limb-sparing procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Indications for amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In certain circumstances, amputation or rotationplasty (see below) may be preferred over limb-sparing surgery for extremity sarcomas. Prosthetic improvements have enhanced the amputee's functional results. Furthermore, some types of amputation do not require the patient to wear a prosthesis, and they are associated with lesser cosmetic and functional deformity as compared with those individuals who have undergone an amputation and need a prosthesis to return to the normal activities of daily living.",
"   </p>",
"   <p>",
"    Although amputation does not preclude a local recurrence, the risk is less than 5 percent. Stump recurrence has been attributed to extensive intramedullary tumor spread and the existence of skip lesions. It is important to assess the joint that is adjacent to the primary extremity sarcoma to determine whether an intraarticular or extraarticular resection will be necessary and to exclude the presence of skip metastases within the involved bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59394 \" href=\"mobipreview.htm?2/47/2801\">",
"     image 1",
"    </a>",
"    ). Among the factors that lessen the likelihood of local recurrence are a wide surgical margin and a good histologic response to neoadjuvant therapy (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Rotationplasty and the skeletally immature patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth considerations following resection and reconstruction are not a major concern for patients with lower extremity lesions who are at or near skeletal maturity or for lesions involving the upper extremity. However, for skeletally immature children with lower extremity lesions, vigorous functional demands, and limb length inequality following a limb-sparing procedure is a major problem. In this setting, surgical options include rotationplasty, amputation, or reconstruction with an expandable metal endoprosthesis. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Allografts and endoprostheses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Van Ness rotationplasty is a surgical technique for lesions involving the femur that was originally described in 1930. It involves resection of the tumor and surrounding tissues as an intercalary amputation, saving only the sciatic nerve, while either twisting and curling the femoral vessels or segmentally resecting a portion of the vessels with a subsequent vascular anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Typically, the distal femur and its adjacent musculature are excised, and the tibia and foot preserved by maintaining an intact neurovascular bundle. The tibia is then fixed with plates and screws to the proximal femur, and the distal extremity rotated 180&ordm;, permitting the foot and ankle to function like a knee (",
"    <a class=\"graphic graphic_picture graphicRef72276 \" href=\"mobipreview.htm?17/27/17840\">",
"     picture 1",
"    </a>",
"    ). The vessels adjacent to the tumor can be resected and reanastomosed if necessary. The retained foot acts as the amputation stump for a transtibial amputation, and this prosthetic arrangement requires less energy expenditure than that required for a transfemoral amputation.",
"   </p>",
"   <p>",
"    Although the appearance of the reconstructed limb is cosmetically displeasing, the major advantage of rotationplasty in the skeletally immature patient is the ability to tailor the limb length at maturity. Functional results are excellent, with patients able to achieve recreational, sporting, and career goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A series of 25 children treated with rotationplasty focused on risk factors for failure and postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/65\">",
"     65",
"    </a>",
"    ]. The majority of cases (22 of 25) produced excellent functional outcome. The few failures were a result of vascular impairment by the tumor, necessitating amputation. Patients with larger tumors, unresponsiveness to chemotherapy, or a preoperative pathologic fracture appeared to be at higher risk of failure.",
"   </p>",
"   <p>",
"    In view of these favorable functional results, rotationplasty is often the reconstructive procedure of choice for children under the age of eight who have proximal lower extremity sarcomas. However, some patients and their families refuse rotationplasty and amputation, and allografts are frequently used to reconstruct the defect in the skeletally immature patient, with standard limb equalizing procedures carried out at a later date. An alternative to allografts is the use of expandable or modular metal prostheses which can be lengthened as the child grows. All of these approaches have limitations, and their advantages and disadvantages in very young patients are discussed below (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Reconstruction techniques'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13145656\">",
"    <span class=\"h3\">",
"     Upper extermity lesions involving the shoulder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of the scapula present an unusual challenge. Although subtotal or complete scapulectomy can be considered for some lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], limb reconstruction is difficult and shoulder morbidity may be substantial. For massive tumors of the shoulder girdle (including the proximal humerus), the Tikhoff-Linberg (interscapulothoracic) resection is an alternative to forequarter amputation as long as resection of the brachial plexus is not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/68\">",
"     68",
"    </a>",
"    ]. The proximal humerus and scapula are resected without the need for bony replacement, and the function of distal arm, elbow, and hand is preserved. Because the resulting shoulder region is unstable, with telescoping of the intervening structures when stresses are applied to the hand or forearm, stabilization is necessary using dacron tape. This is usually sufficient to prevent telescoping and stress to the remaining neurovascular structures. When the scapula can be preserved, an arthrodesis with or without allograft can be attempted even if the surrounding deltoid and rotator cuff musculature requires resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Non-extremity lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles derived from extremity sarcoma resections have now been applied to the axial structures. Osteosarcomas involving the axial skeleton have a worse prognosis than those involving the extremities, in part due to the difficulty in achieving complete surgical resection in these difficult locations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. In particular, primary malignant non-extremity tumors are more difficult to resect secondary to their large size, surrounding neurologic and vascular structures, reconstructive challenges, and frequent comorbidities.",
"   </p>",
"   <p>",
"    Pelvic and spine tumors are associated with unique challenges. In the spine, en bloc resections may be intralesional, marginal, or wide. Radical resections or removing the entire epidural space is not feasible. The dura and epidural space offer a unique region for tumor management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pelvic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic tumors represent a unique challenge. A tumor arising in the pelvis can involve a segment of nonarticular bone, the acetabulum, or both. En bloc excision of the hemipelvis with preservation of the extremity (internal hemipelvectomy) produces equivalent oncologic results when compared to external formal hemipelvectomy (hindquarter amputation) and better functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. It is preferred over external hemipelvectomy, usually because of patient preference.",
"   </p>",
"   <p>",
"    External hemipelvectomy may be necessary in up to one-third of patients, and despite this, local recurrence rates are high because of difficulty obtaining adequate margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. In a large series of 67 patients with pelvic osteosarcoma, 50 underwent surgical excision, 12 of whom required external hemipelvectomy; the remainder had limb-sparing procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/76\">",
"     76",
"    </a>",
"    ]. The incidence of local recurrence overall was 70 percent, and it was 62 percent for those undergoing definitive surgery. Despite the use of multiagent systemic chemotherapy, the five-year overall and progression-free survival rates were only 27 and 19 percent, respectively. Postoperative radiation therapy improved the outcome for patients with an intralesional or no surgical excision.",
"   </p>",
"   <p>",
"    Hemipelvectomy has been combined with intraoperative radiation therapy (IORT) in an attempt to improve local control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/78\">",
"     78",
"    </a>",
"    ]. Initial results are promising, but further clinical experience is needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link&amp;anchor=H19#H19\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Radiation schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of resection determines the functional deficit and influences the decision regarding the type of reconstruction, if any, to optimize function. An internal hemipelvectomy may not require allograft or a metallic endoprosthesis reconstruction. Resection without reconstruction is a reasonable option, particularly in view of the high complication rate with reconstruction of pelvic defects using allografts (approximately 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/79\">",
"     79",
"    </a>",
"    ]. The femur and remaining pelvis can be left flail and the gap is bridged by scar tissue, or postoperative traction can be applied to initiate the development of scar tissue. Although this allows for stable weight bearing, it also results in a significant limb length inequality, and most patients require crutches for ambulation.",
"   </p>",
"   <p>",
"    Metallic endoprosthesis reconstruction (saddle prosthesis) has occasionally been successful, but fixation is extremely difficult and prosthesis loosening can be a problem long-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/73,80,81\">",
"     73,80,81",
"    </a>",
"    ]. Another method of obtaining structural integrity is to fuse the proximal femur to the ilium or sacrum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/82\">",
"     82",
"    </a>",
"    ]. The choice of procedure is dependent on the clinical situation and the surgeon and patient preference, but they in general offer reasonable alternatives to external hemipelvectomy, with superior functional and psychological results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Spine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spine presents a particularly difficult problem with regard to surgical margins. Local recurrence rates are closely tied to surgical margin status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/69\">",
"     69",
"    </a>",
"    ]. In one report of 30 patients with primary sarcomas of the mobile spine, the resection was classified as wide, marginal or intralesional in 23, 10, and 67 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/83\">",
"     83",
"    </a>",
"    ]. Resection margins were histologically positive in 60 percent and associated with a fivefold increased risk of a local recurrence. At least one series suggests an advantage for either wide or marginal surgery compared to intralesional or no surgery for osteosarcomas of the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/69\">",
"     69",
"    </a>",
"    ]. They recommended that these patients be treated with a combination of chemotherapy and at least marginal surgery.",
"   </p>",
"   <p>",
"    En bloc resection (vertebrectomy) followed by stabilization and fusion is possible with wide margins in some cases as long as dural invasion is absent. If the tumor abuts or invades the dura (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68317 \" href=\"mobipreview.htm?27/3/27698\">",
"     image 4",
"    </a>",
"    ), a segment can be excised. However, this procedure may be accompanied by seeding of tumor cells into the cerebrospinal fluid. Postoperative (adjuvant) radiation therapy can be employed to manage a microscopically positive dural margin. Largely because of the potential for dural involvement, local recurrence rates are higher for tumors located in the vertebral body and posterior elements (particularly those with extra-osseous extension into the canal and paraspinal region) as compared to the anterior vertebral column.",
"   </p>",
"   <p>",
"    Patients with sacral tumors do especially poorly. In one report that included 22 patients with primary high-grade osteosarcoma of the spine or sacrum, all of whom received neoadjuvant chemotherapy, only two of the 12 who underwent surgery had wide excision to negative margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/69\">",
"     69",
"    </a>",
"    ]. Although total sacrectomy may improve local control, neurologic and sexual dysfunction is inevitable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/84\">",
"     84",
"    </a>",
"    ]. Local recurrence may still develop despite maximal surgical resection and intraoperative or postoperative radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/70,78\">",
"     70,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperative radiotherapy may be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/69\">",
"     69",
"    </a>",
"    ]. Newer methods of adjuvant radiation therapy, including combined proton beam and photon irradiation using three dimensional conformal techniques, may permit a higher dose of radiation to be administered while sparing adjacent normal tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allograft reconstruction is an effective means of filling the massive osseous defects following spine resection. Combined anterior and posterior instrumentation provides the best stability following tumor vertebral body resection. In the anterior spine, femoral and humeral shafts used to substitute for resected vertebral bodies have provided excellent stability. Metal cages provide an alternative to allografts in the anterior spine, and they do not require biologic healing of the graft to the host bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/86\">",
"     86",
"    </a>",
"    ]. New posterior instrumentation, bone graft products, and pedicle screws provide improved fixation and better rates of fusion. In setting where radiation therapy has been used to improve local control, complications such as fractures and non-unions may occur more frequently. The bridging of a large osseous defect may also be augmented with vascularized grafts. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Vascularized grafts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECONSTRUCTION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with osteosarcoma will require reconstructive procedures in order to restore structural integrity. However, some locations and circumstances do not always require reconstruction to deal with the surgical defect. As an example, pelvic tumors may not require postresection reconstruction following an internal hemipelvectomy (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Non-extremity lesions'",
"    </a>",
"    above). Expendable bones that do not require replacement include the ulna, patella, fibula, scapula, and ribs. Resection techniques for tumors in these locations are well described, and the resultant functional disability without bony reconstruction is frequently minimal with the exception of complete scapulectomy, which may result in significant morbidity, especially if muscle loss is great.",
"   </p>",
"   <p>",
"    For patients who do require reconstruction, available methods include metal",
"    <span class=\"nowrap\">",
"     endoprostheses/hardware,",
"    </span>",
"    allografts, arthrodeses, vascularized fibular transfers, rotationplasty, and various unusual methods that are specific for certain anatomic locations. The choice of reconstructive method should be individualized. The following factors influence the selection of a reconstructive method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/87\">",
"     87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anatomic location and integrity of the surrounding structures",
"     </li>",
"     <li>",
"      The stage of disease and extent of resection",
"     </li>",
"     <li>",
"      The tissue diagnosis",
"     </li>",
"     <li>",
"      Preference of the surgeon",
"     </li>",
"     <li>",
"      The likelihood and nature of complications related to a particular type of reconstruction",
"     </li>",
"     <li>",
"      The patient's age, expectations, and anticipated functional demands",
"     </li>",
"     <li>",
"      The availability of the materials for the reconstructive procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the majority of patients receive preoperative (neoadjuvant) chemotherapy, planning of the surgical procedure is essential in order to coordinate chemotherapy schedules and anticipated bone marrow recovery with the time needed to manufacture a prosthesis or procure the necessary reconstructive materials.",
"   </p>",
"   <p>",
"    An understanding of the capabilities and limitations of available reconstructive techniques is necessary so that the appropriate method is chosen for the surgical reconstruction. A brief description of some of these techniques follows. Rotationplasty is discussed above. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Rotationplasty and the skeletally immature patient'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Allografts and endoprostheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allografts and metal endoprostheses are common means of reconstructing bone defects that result from sarcoma surgery. Other methods listed below may be preferred to fill the osseous defect depending on the clinical situation and the availability of the product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Allografts",
"    </span>",
"    &nbsp;&mdash;&nbsp;While autologous bone grafting is of limited use in patients undergoing resection of bone tumors because of the large size of the defect, allografts have been successfully used for many years. Allografts provide the potential for long-lasting reconstruction of large bony defects by providing a structural lattice for the ingrowth of the patient's own bone elements (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56694 \" href=\"mobipreview.htm?14/49/15135\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/88-94\">",
"     88-94",
"    </a>",
"    ]. The host normal tissue slowly invades the allograft by creeping substitution of normal bone and vascular elements at the osteosynthesis site and periosteum. Large segments of allografted bone probably do not completely fill with autogenous bone, and this may lead to allograft fracture over time (this occurs in about 18 percent of the cases). The articular cartilage is slowly replaced by an inflammatory pannus-like tissue, and some patients may ultimately require joint resurfacing.",
"   </p>",
"   <p>",
"    Allografts are available from tissue banks and need to be matched to the size of the resected bone. Although bone is a relative nonantigenic structure, matching for the class II major histocompatibility antigens results in better clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Freezing further decreases the likelihood of immune rejection, and the addition of glycerol or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=see_link\">",
"     dimethyl sulfoxide",
"    </a>",
"    during freezing preserves the articular cartilage somewhat. Soft tissues are left attached to the allograft to increase function by providing a site of attachment for host soft tissues. This is particularly important for reconstructions around the knee.",
"   </p>",
"   <p>",
"    The major advantages of allografts over endoprosthetic reconstruction are restoration of bone stock, sparing of the uninvolved portion of adjacent joints, and providing a site of attachment for host soft tissues. Intercalary allograft reconstructions tend to perform better than osteoarticular grafts, and clearly better than allograft arthrodeses, which have the highest rate of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some disadvantages to allografts. Compared to metal endoprostheses, allografts must be fixed to the host bone and allowed to heal. Thus, they must be protected from weight bearing for prolonged periods. Early complication rates (15 to 20 percent) are higher than those seen in patients undergoing placement of metal prostheses. While implant loosening does not occur as it does for metal prostheses, nonunion and fractures may result in allograft failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/98\">",
"     98",
"    </a>",
"    ]. As with endoprosthetic reconstructions, infection in the reconstructed site is devastating and may necessitate amputation of the extremity. Late complications include degenerative arthritis and joint instability. Despite these limitations, satisfactory functional results are achieved in 70 percent of patients undergoing allografting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/89,93,99,100\">",
"     89,93,99,100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Metal endoprostheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, the metallic implants that were used to reconstruct bone defects following tumor resection were custom made and manufactured for specific patient requirements. More recently, modular metal prostheses have become available that permit reconstruction without having to resort to a custom implant. The components are readily available and can be assembled at the time of surgery to match the extent of the defect (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50945 \" href=\"mobipreview.htm?38/43/39614\">",
"     image 6",
"    </a>",
"    ). Modular metal prosthetic reconstructions are performed most frequently about the shoulder, hip, and knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Total femoral reconstructions have been performed in certain circumstances.",
"   </p>",
"   <p>",
"    Most bone tumors are located adjacent to joints, and metal endoprostheses are well suited to joint replacement. The implants used for reconstruction after sarcoma surgery are similar to those that are used in patients with arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=see_link\">",
"     \"Total joint replacement for severe rheumatoid arthritis\"",
"    </a>",
"    .) As compared to allografts, endoprostheses allow for immediate joint stability and early weight bearing. However, they are not free of complications, which include fatigue fracture, loosening, and infection. The fatigue fracture potential of the metal is a design and stress problem that can be potentially improved by manufacturing changes.",
"   </p>",
"   <p>",
"    Loosening at the bone-cement interface is a function of repetitive stresses during activities of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/87,103\">",
"     87,103",
"    </a>",
"    ]. Loosening can be minimized by using a meticulous cementing technique and stress-reducing total joint mechanics such as a rotating-hinge knee design. Nevertheless, most, if not all, implants will need to be replaced at some point in the long-term survivor's lifetime. The survivorship of the prosthetic arthroplasty reconstruction varies, and ranges from 60 to 90 percent estimated survival at five years to 40 to 80 percent at ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/102,104-106\">",
"     102,104-106",
"    </a>",
"    ]. These data have generated the impetus for development of cementless or press-fit implants. Implants placed without cement may have a better long term survival, but this is a controversial area.",
"   </p>",
"   <p>",
"    Because the prostheses act as a large foreign body, infections, which occur in 2 to 5 percent of cases, are difficult to treat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/87,102,104,105,107\">",
"     87,102,104,105,107",
"    </a>",
"    ]. Deep infections usually require removal of the implant and sometimes an amputation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Expandable prostheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expandable prostheses have been developed for reconstruction in skeletally immature children with malignant bone tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. Different types of prostheses are available; one type has a telescoping unit that can be expanded using a gear device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/110,111\">",
"     110,111",
"    </a>",
"    ], and another employs the principle of a loaded spring which is gradually released via external exposure to an electromagnetic field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/112\">",
"     112",
"    </a>",
"    ]. Because these devices permit an expansion of the overall length of the prosthesis, they can be implanted in skeletally immature patients, increasing the numbers of those eligible for limb-salvage surgery.",
"   </p>",
"   <p>",
"    Estimation of growth potential in the younger child is important in determining whether this means of reconstruction is appropriate for the situation. The Lewis Expandable Adjustable Prosthesis (LEAP) was initially successful in young patients (five to eight years). However, newer expandable prostheses that can be lengthened without invasive surgery are popular in this age group. One of these, the Phoenix, uses a magnetic field to provide the energy to lengthen the prosthesis.",
"   </p>",
"   <p>",
"    The modular prostheses are better for large preadolescent and adolescent children. Most children require several lengthenings in those prostheses, and it is frequently necessary to excise the pseudocapsule around the implant to gain length; as a result, the lengthening procedures are not small operations.",
"   </p>",
"   <p>",
"    Expandable prostheses frequently require replacement after they have been fully extended because they lose some structural strength. Difficulties in using this prosthesis occur primarily in the rehabilitation phase, but loosening, fatigue failure of the implant, and inability to gain equal limb lengths can also occur. Close follow-up is crucial to optimize the functional outcome and properly time periodic lengthenings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Allograft-prosthetic composites",
"    </span>",
"    &nbsp;&mdash;&nbsp;For extremity reconstructions, allografts can be combined with metal prostheses (the prosthesis is cemented to the allograft) to form what is called an allograft-prosthetic composite, or alloprosthesis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68999 \" href=\"mobipreview.htm?21/35/22079\">",
"     image 7",
"    </a>",
"    ). This has certain advantages over allografts or metal prostheses alone. Since the articular surface is formed by the metal portion of the construct, it does not fracture or collapse as may happen with osteoarticular allografts. The allograft portion of the composite restores bone stock and provides soft tissue attachment points for insertion of muscle tendons. Even though a great deal of research has been done to improve attachments of muscle units to prostheses, this is still an unsolved problem with this type of reconstruction. Alloprosthetic reconstructions usually result in good or excellent functional results, but the operation is more complex and time consuming than either osteoarticular allografts or prostheses alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arthrodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthrodesis (joint fusion) is important for tumors involving the spine; otherwise, the hardware fails as a result of nonunion, and pain may be a persistent complaint. In the spine almost all fusions require implantation of bone graft material. Transplantation of structured or morcelized autologous corticocancellous bone obtained from the iliac crest is the most frequently used technique.",
"   </p>",
"   <p>",
"    Arthrodesis may also be considered for selected patients with extremity lesions. Although a nonmobile joint is less desirable than a mobile one to the majority of patients, it may provide the best mode of reconstruction in certain cases and is one method by which durable function can be achieved. Arthrodesis of various joints following extraarticular resection of malignant bone tumors may be the best reconstructive option if resection includes most of the surrounding joint soft tissues and joint arthroplasty cannot be accomplished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/114,115\">",
"     114,115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common joints that are considered for arthrodeses following resection of bone sarcomas resection are the hip, knee, and shoulder. Hip and shoulder arthrodeses do not produce as much functional disability as knee fusions because of the capacity for excellent compensatory motion at other joints in the affected extremity. Despite functional limitations, knee arthrodesis can be achieved in the majority of patients, even when a long segment of bone has been excised. However, this procedure is complicated by a high incidence of nonunion, fatigue fracture, and infection. Although the operation successfully achieves tumor-free margins, the revascularization and rehabilitation processes are prolonged and complicated. Patients must adjust their lifestyles to accommodate the arthrodesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vascularized grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascularized bone grafts are also used to reconstruct osseous defects and augment other reconstructive techniques, such as intercalary allograft segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. They are of particular benefit in the treatment of allograft nonunions and fractures and in surgical beds which have poor vascularity and perfusion following radiation. If the vascular graft remains viable, healing occurs more rapidly than with nonvascularized grafts and is a more durable construct.",
"   </p>",
"   <p>",
"    The surgical procedure for implantation of a vascularized graft is lengthy and the vascular anastomosis is technically demanding. One of the most commonly used grafts for this purpose is the fibula; fortunately, donor site complications are rare. Vascularized fibular grafts have also been used to augment healing of intercalary grafts following intraepiphyseal resections of the distal femur and proximal tibia, where only a short segment of epiphyseal bone remains for fixation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, more than 80 percent of patients with osteosarcoma or Ewing sarcoma treated with surgery alone develop metastatic disease, despite having adequate local tumor control. It is surmised that subclinical metastatic disease is present at diagnosis, even in the absence of overt metastases. Chemotherapy can eradicate these deposits if initiated at a time when disease burden is low. As a result, adjuvant chemotherapy is considered a standard component of management for these primary bone tumors.",
"   </p>",
"   <p>",
"    For osteosarcoma, postoperative chemotherapy was used initially, and five year overall survival rates rose from less than 20 percent to between 40 and 60 percent in the 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/118\">",
"     118",
"    </a>",
"    ]. Two subsequent randomized studies conducted in the 1980s demonstrated a significant relapse-free and overall survival benefit for adjuvant chemotherapy, although the trials were limited in size, and the survival benefits were modest. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with osteosarcoma, presurgical or neoadjuvant chemotherapy was originally considered because of the time needed for fabrication of custom metallic implants; chemotherapy was given while awaiting definitive surgery. Due to its success in shrinking tumors, neoadjuvant chemotherapy evolved to a method of increasing the proportion of patients who were suitable candidates for limb-salvage surgery and to facilitate limb-sparing procedures by diminishing tumor burden. A major concern in this regard is the possibility that inexperienced surgeons may expand selection criteria to accommodate inappropriate candidates who might be better served by amputation. Adjuvant chemotherapy is never a substitute for sound surgical principles.",
"   </p>",
"   <p>",
"    One of the most compelling rationales for neoadjuvant chemotherapy is its ability to function as an in vivo drug trial to determine the drug sensitivity of an individual tumor and to customize postoperative therapy. A grading system for assessing the effect of preoperative chemotherapy in osteosarcoma was developed at Memorial Sloan Kettering and is in widespread use (",
"    <a class=\"graphic graphic_table graphicRef58829 \" href=\"mobipreview.htm?13/58/14251\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to neoadjuvant chemotherapy is a major prognostic factor. Patients with a near-complete absence of viable tumor cells in the resection specimen after neoadjuvant therapy do well when the same therapy is continued after surgery. In contrast, if the tumor contains 10 percent or more residual viable cells after neoadjuvant chemotherapy, a change in the chemotherapeutic regimen might be beneficial, although this is a controversial area. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of limb-sparing surgical procedures for osteosarcoma are performed at institutions using presurgical chemotherapy. On the other hand, immediate resection is an acceptable option in situations where the surgical procedure would not be changed by a good response to neoadjuvant chemotherapy. In such cases, adjuvant chemotherapy should be administered postoperatively.",
"   </p>",
"   <p>",
"    Issues surrounding the use of neoadjuvant and adjuvant chemotherapy for Ewing sarcoma are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike Ewing sarcoma, conventional osteosarcoma is relatively resistant to radiation therapy. Because of this, primary radiation therapy is not usually adequate to achieve local disease control, particularly for bulky tumors. Issues surrounding the use of radiation therapy for Ewing sarcoma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been renewed interest in a potential role for radiation therapy for patients with osteosarcoma whose tumors respond to chemotherapy and in whom surgery would be debilitating. A recent report described a five-year local control rate of 56 percent among 31 patients with nonmetastatic extremity osteosarcoma who refused surgery and were instead treated with radiotherapy (median dose 60 Gy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/119\">",
"     119",
"    </a>",
"    ]. No local failures developed in 11 patients who responded well to chemotherapy with both a radiographic and biochemical response (normalization of alkaline phosphatase), and the five-year metastasis-free survival rate was 91 percent. Among patients who achieved local control, 86 percent had \"excellent\" limb function.",
"   </p>",
"   <p>",
"    Although local adjuvant radiation therapy and prophylactic whole lung radiation have been used in an attempt to improve outcomes following surgery, neither is effective in the absence of systemic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/13,120,121\">",
"     13,120,121",
"    </a>",
"    ]. Furthermore, in patients treated with effective surgery and chemotherapy, adjuvant radiation does not improve survival and increases the risk for secondary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/122\">",
"     122",
"    </a>",
"    ]. Adjuvant radiation should be considered only in the setting of an unresectable or incompletely resected primary tumor or in patients with the small cell variant of osteosarcoma, which may be more radiosensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/51/37690/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of adjuvant radiation therapy in patients with Ewing sarcoma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/48/27394?source=see_link\">",
"       \"Patient information: Chondrosarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteosarcoma is the most common primary malignant tumor of bone; other less common types of bone sarcoma include peripheral primitive neuroectodermal tumor",
"      <span class=\"nowrap\">",
"       (PNET)/Ewing",
"      </span>",
"      sarcoma, malignant fibrous histiocytoma, fibrosarcoma, chondrosarcoma, and chordoma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of the preoperative evaluation for a primary bone sarcoma is to establish the tissue diagnosis, evaluate disease extent, and assess the feasibility of a limb-sparing approach. Clinical staging includes all of the data obtained prior to definitive therapy, including the results of imaging, physical examination, laboratory studies, and tissue biopsy. The biopsy must be carefully planned to ensure that adequate tissue is obtained for diagnosis without compromising the opportunity for limb salvage. Biopsies should take place after the completion of the staging studies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery and systemic chemotherapy are the mainstays of treatment for patients with osteosarcomas and other primary bone tumors such as fibrosarcoma of bone. Chondrosarcoma and chordoma have not been routinely or historically treated with chemotherapy or radiation and therefore surgery is the mainstay of management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"       \"Chondrosarcoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"       \"Chordoma and chondrosarcoma of the skull base\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7161?source=see_link&amp;anchor=H20#H20\">",
"       \"Spinal cord tumors\", section on 'Chordomas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although there is no specific survival benefit to preoperative as compared to postoperative chemotherapy in osteosarcoma patients, the neoadjuvant approach may permit a greater number of patients to undergo limb-sparing procedures. However, chemotherapy is no substitute for sound surgical judgment when assessing the need for amputation versus limb-sparing surgery. The optimal chemotherapy regimen has not been established. In general, patients with a nearly complete response to neoadjuvant chemotherapy do better than those with a lesser response. Even if the patient has a chemosensitive tumor, it may be reasonable to proceed to immediate surgery followed by adjuvant chemotherapy if the nature of the resection would not necessarily be influenced by a good response to chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H4#H4\">",
"       \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27\">",
"       'Neoadjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reconstructive options vary depending upon the factors listed above. In addition, there is surgeon preference and no absolute consensus in many circumstances as to the optimal reconstructive method. In some circumstances, if the tumor is located in an expendable bone, reconstruction is not even necessary. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Reconstruction techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no role for adjuvant radiation therapy except in patients with unresectable or incompletely resected sarcomas and possibly in the rare patient with a small cell osteosarcoma. Radiation therapy for local control can be used in patients who decline surgery or for whom there is no effective surgical option. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In contrast to osteosarcoma and other primary bone sarcomas, Ewing sarcoma is more radiosensitive, and radiation may be considered an effective option for local control. Although modern treatment protocols emphasize surgery for optimal local control, patients who lack a function-preserving surgical option because of tumor location or extent, and those who have clearly unresectable primary tumors following induction chemotherapy are appropriate candidates for radiation therapy. Furthermore, adjuvant radiation may be considered for bulky tumors in difficult sites (eg, the pelvis), if there is residual microscopic or gross disease after surgery, and for patients with high-risk chest wall primary tumors (close or involved margins, initial pleural effusion, pleural infiltration, and intraoperative contamination of the pleural space). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=see_link&amp;anchor=H7#H7\">",
"       \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Adjuvant RT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Huvos A. Bone Tumors: Diagnosis, Treatment, Prognosis, 2nd, WB Saunders, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/2\">",
"      Sissons HA. The WHO classification of bone tumors. Recent Results Cancer Res 1976; :104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/3\">",
"      McKenna R, Schwinn C, Soong K, et al. Sarcomas of the osteogenic series (osteosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. J Bone Joint Surg Am 1966; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (Pub #99-4649), Ries LA, Smith MAS, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.99.",
"    </li>",
"    <li>",
"     Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000 (NIH Pub. No. 06-5767), Bleyer A, O&rsquo;Leary M, Barr R, Ries LAG (Eds), National Cancer Institute, Bethesda, MD 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/6\">",
"      Bruland OS, H&oslash;if&oslash;dt H, Saeter G, et al. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005; 11:4666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/7\">",
"      Duffaud F, Digue L, Baciuchka-Palmaro M, et al. Osteosarcomas of flat bones in adolescents and adults. Cancer 2000; 88:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/8\">",
"      Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997; 79:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/9\">",
"      Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16:3641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/10\">",
"      Yonemoto T, Tatezaki S, Ishii T, et al. Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res 1998; :194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/11\">",
"      Kager L, Zoubek A, P&ouml;tschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/12\">",
"      Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 2007; 96:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/13\">",
"      Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/14\">",
"      Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer 1975; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/15\">",
"      Bhagia SM, Grimer RJ, Davies AM, Mangham DC. Scintigraphically negative skip metastasis in osteosarcoma. Eur Radiol 1997; 7:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/16\">",
"      Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/17\">",
"      Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/18\">",
"      Ward WG Sr, Kilpatrick S. Fine needle aspiration biopsy of primary bone tumors. Clin Orthop Relat Res 2000; :80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/19\">",
"      Hau A, Kim I, Kattapuram S, et al. Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 2002; 31:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/20\">",
"      Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; :9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/21\">",
"      Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 1996; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Spring, New York 2010. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/23\">",
"      Inwards CY, Unni KK. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/24\">",
"      Nakajima H, Sim FH, Bond JR, Unni KK. Small cell osteosarcoma of bone. Review of 72 cases. Cancer 1997; 79:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/25\">",
"      Weiss A, Khoury JD, Hoffer FA, et al. Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Cancer 2007; 109:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/26\">",
"      Rosen G, Huvos AG, Marcove R, Nirenberg A. Telangiectatic osteogenic sarcoma. Improved survival with combination chemotherapy. Clin Orthop Relat Res 1986; :164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/27\">",
"      Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol 1997; 8:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/28\">",
"      Teng H, Xinghai Y, Wei H, et al. Malignant fibrous histiocytoma of the spine: a series of 13 clinical case reports and review of 17 published cases. Spine (Phila Pa 1976) 2011; 36:E1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/29\">",
"      Schajowicz F, McGuire MH, Santini Araujo E, et al. Osteosarcomas arising on the surfaces of long bones. J Bone Joint Surg Am 1988; 70:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/30\">",
"      Raymond AK. Surface osteosarcoma. Clin Orthop Relat Res 1991; :140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/31\">",
"      Staals EL, Bacchini P, Bertoni F. High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute. Cancer 2008; 112:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/32\">",
"      Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer 1996; 78:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/33\">",
"      Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma--a European review of outcome. Eur J Cancer 2005; 41:2806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/34\">",
"      Palmerini E, Maki RG, Staals EL, et al. Primary Angiosarcoma of Bone: A Retrospective Analysis of 60 Patients From 2 Institutions. Am J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/35\">",
"      Jaffe N, Carrasco H, Raymond K, et al. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 2002; 95:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/36\">",
"      Peabody TD, Gibbs CP Jr, Simon MA. Evaluation and staging of musculoskeletal neoplasms. J Bone Joint Surg Am 1998; 80:1204.",
"     </a>",
"    </li>",
"    <li>",
"     Enneking WF. A system for evaluation of the surgical management of musculoskeletal tumors. In: Enneking WF, Limb salvage in musculoskeletal oncology (Ed), Churchill Livingstone, New York 1987. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/38\">",
"      Grimer RJ, Taminiau AM, Cannon SR, Surgical Subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 2002; 84:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/39\">",
"      Wittig JC, Bickels J, Kellar-Graney KL, et al. Osteosarcoma of the proximal humerus: long-term results with limb-sparing surgery. Clin Orthop Relat Res 2002; :156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/40\">",
"      Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol 2002; 20:4493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/41\">",
"      Nagarajan R, Neglia JP, Clohisy DR, et al. Education, employment, insurance, and marital status among 694 survivors of pediatric lower extremity bone tumors: a report from the childhood cancer survivor study. Cancer 2003; 97:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/42\">",
"      Zahlten-Hinguranage A, Bernd L, Ewerbeck V, Sabo D. Equal quality of life after limb-sparing or ablative surgery for lower extremity sarcomas. Br J Cancer 2004; 91:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/43\">",
"      Nagarajan R, Clohisy DR, Neglia JP, et al. Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the Childhood Cancer Survivor Study. Br J Cancer 2004; 91:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/44\">",
"      Bekkering WP, Vliet Vlieland TP, Koopman HM, et al. Functional ability and physical activity in children and young adults after limb-salvage or ablative surgery for lower extremity bone tumors. J Surg Oncol 2011; 103:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/45\">",
"      Renard AJ, Veth RP, Schreuder HW, et al. Function and complications after ablative and limb-salvage therapy in lower extremity sarcoma of bone. J Surg Oncol 2000; 73:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/46\">",
"      Rougraff BT, Simon MA, Kneisl JS, et al. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994; 76:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/47\">",
"      Weeden S, Grimer RJ, Cannon SR, et al. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001; 37:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/48\">",
"      Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 1986; 68:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/49\">",
"      Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/50\">",
"      Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer 2004; 100:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/51\">",
"      Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996; 14:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/52\">",
"      Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop Relat Res 1999; :83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/53\">",
"      Brosj&ouml; O. Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 1999; 285:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/54\">",
"      Scully SP, Ghert MA, Zurakowski D, et al. Pathologic fracture in osteosarcoma : prognostic importance and treatment implications. J Bone Joint Surg Am 2002; 84-A:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/55\">",
"      Jaffe N, Spears R, Eftekhari F, et al. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer 1987; 59:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/56\">",
"      Scully SP, Temple HT, O'Keefe RJ, et al. The surgical treatment of patients with osteosarcoma who sustain a pathologic fracture. Clin Orthop Relat Res 1996; :227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/57\">",
"      Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18:4016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/58\">",
"      Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001; 12:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/59\">",
"      Ferguson PC, McLaughlin CE, Griffin AM, et al. Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma. J Surg Oncol 2010; 102:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/60\">",
"      Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002; 84:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/61\">",
"      Winkelmann WW. Rotationplasty. Orthop Clin North Am 1996; 27:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/62\">",
"      Hanlon M, Krajbich JI. Rotationplasty in skeletally immature patients. Long-term followup results. Clin Orthop Relat Res 1999; :75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/63\">",
"      Winkelmann WW. Type-B-IIIa hip rotationplasty: an alternative operation for the treatment of malignant tumors of the femur in early childhood. J Bone Joint Surg Am 2000; 82:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/64\">",
"      Hillmann A, Hoffmann C, Gosheger G, et al. Malignant tumor of the distal part of the femur or the proximal part of the tibia: endoprosthetic replacement or rotationplasty. Functional outcome and quality-of-life measurements. J Bone Joint Surg Am 1999; 81:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/65\">",
"      Sawamura C, Hornicek FJ, Gebhardt MC. Complications and risk factors for failure of rotationplasty: review of 25 patients. Clin Orthop Relat Res 2008; 466:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/66\">",
"      Gibbons CL, Bell RS, Wunder JS, et al. Function after subtotal scapulectomy for neoplasm of bone and soft tissue. J Bone Joint Surg Br 1998; 80:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/67\">",
"      Rodriguez JA, Craven JE, Heinrich S, et al. Current role of scapulectomy. Am Surg 1999; 65:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/68\">",
"      Voggenreiter G, Assenmacher S, Schmit-Neuerburg KP. Tikhoff-Linberg procedure for bone and soft tissue tumors of the shoulder girdle. Arch Surg 1999; 134:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/69\">",
"      Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer 2002; 94:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/70\">",
"      Shives TC, Dahlin DC, Sim FH, et al. Osteosarcoma of the spine. J Bone Joint Surg Am 1986; 68:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/71\">",
"      Bielack SS, Wulff B, Delling G, et al. Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma study group (COSS). Med Pediatr Oncol 1995; 24:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/72\">",
"      Wirbel RJ, Schulte M, Mutschler WE. Surgical treatment of pelvic sarcomas: oncologic and functional outcome. Clin Orthop Relat Res 2001; :190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/73\">",
"      Cottias P, Jeanrot C, Vinh TS, et al. Complications and functional evaluation of 17 saddle prostheses for resection of periacetabular tumors. J Surg Oncol 2001; 78:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/74\">",
"      Kawai A, Huvos AG, Meyers PA, Healey JH. Osteosarcoma of the pelvis. Oncologic results of 40 patients. Clin Orthop Relat Res 1998; :196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/75\">",
"      Grimer RJ, Carter SR, Tillman RM, et al. Osteosarcoma of the pelvis. J Bone Joint Surg Br 1999; 81:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/76\">",
"      Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003; 21:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/77\">",
"      Saab R, Rao BN, Rodriguez-Galindo C, et al. Osteosarcoma of the pelvis in children and young adults: the St. Jude Children's Research Hospital experience. Cancer 2005; 103:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/78\">",
"      Hoekstra HJ, Sindelar WF, Szabo BG, Kinsella TJ. Hemipelvectomy and intraoperative radiotherapy for bone and soft tissue sarcomas of the pelvic girdle. Radiother Oncol 1995; 37:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/79\">",
"      Aboulafia AJ, Buch R, Mathews J, et al. Reconstruction using the saddle prosthesis following excision of primary and metastatic periacetabular tumors. Clin Orthop Relat Res 1995; :203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/80\">",
"      Rubert CK, Malawer MM, Rosenthal JL. Reconstruction with the saddle prosthesis: Indications, surgical technique, and results. Semin Arthroplasty 1999; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/81\">",
"      Renard AJ, Veth RP, Schreuder HW, et al. The saddle prosthesis in pelvic primary and secondary musculoskeletal tumors: functional results at several postoperative intervals. Arch Orthop Trauma Surg 2000; 120:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/82\">",
"      Fuchs B, O'Connor MI, Kaufman KR, et al. Iliofemoral arthrodesis and pseudarthrosis: a long-term functional outcome evaluation. Clin Orthop Relat Res 2002; :29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/83\">",
"      Talac R, Yaszemski MJ, Currier BL, et al. Relationship between surgical margins and local recurrence in sarcomas of the spine. Clin Orthop Relat Res 2002; :127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/84\">",
"      Wuisman P, Lieshout O, Sugihara S, van Dijk M. Total sacrectomy and reconstruction: oncologic and functional outcome. Clin Orthop Relat Res 2000; :192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/85\">",
"      Hug EB, Fitzek MM, Liebsch NJ, Munzenrider JE. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 1995; 31:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/86\">",
"      Vahldiek MJ, Panjabi MM. Stability potential of spinal instrumentations in tumor vertebral body replacement surgery. Spine (Phila Pa 1976) 1998; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/87\">",
"      Yasko AW, Johnson ME. Surgical management of primary bone sarcomas. Hematol Oncol Clin North Am 1995; 9:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/88\">",
"      Alman BA, De Bari A, Krajbich JI. Massive allografts in the treatment of osteosarcoma and Ewing sarcoma in children and adolescents. J Bone Joint Surg Am 1995; 77:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/89\">",
"      Brien EW, Terek RM, Healey JH, Lane JM. Allograft reconstruction after proximal tibial resection for bone tumors. An analysis of function and outcome comparing allograft and prosthetic reconstructions. Clin Orthop Relat Res 1994; :116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/90\">",
"      Clohisy DR, Mankin HJ. Osteoarticular allografts for reconstruction after resection of a musculoskeletal tumor in the proximal end of the tibia. J Bone Joint Surg Am 1994; 76:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/91\">",
"      Malawer MM, Chou LB. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am 1995; 77:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/92\">",
"      Mnaymneh W, Malinin TI, Lackman RD, et al. Massive distal femoral osteoarticular allografts after resection of bone tumors. Clin Orthop Relat Res 1994; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/93\">",
"      Gebhardt MC, Flugstad DI, Springfield DS, Mankin HJ. The use of bone allografts for limb salvage in high-grade extremity osteosarcoma. Clin Orthop Relat Res 1991; :181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/94\">",
"      Mankin HJ, Gebhardt MC, Jennings LC, et al. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop Relat Res 1996; :86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/95\">",
"      Muscolo DL, Ayerza MA, Calabrese ME, et al. Human leukocyte antigen matching, radiographic score, and histologic findings in massive frozen bone allografts. Clin Orthop Relat Res 1996; :115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/96\">",
"      Friedlaender GE, Strong DM, Tomford WW, Mankin HJ. Long-term follow-up of patients with osteochondral allografts. A correlation between immunologic responses and clinical outcome. Orthop Clin North Am 1999; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/97\">",
"      Donati D, Giacomini S, Gozzi E, et al. Allograft arthrodesis treatment of bone tumors: a two-center study. Clin Orthop Relat Res 2002; :217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/98\">",
"      Hornicek FJ, Gebhardt MC, Tomford WW, et al. Factors affecting nonunion of the allograft-host junction. Clin Orthop Relat Res 2001; :87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/99\">",
"      Hornicek FJ Jr, Mnaymneh W, Lackman RD, et al. Limb salvage with osteoarticular allografts after resection of proximal tibia bone tumors. Clin Orthop Relat Res 1998; :179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/100\">",
"      Donati D, Di Liddo M, Zavatta M, et al. Massive bone allograft reconstruction in high-grade osteosarcoma. Clin Orthop Relat Res 2000; :186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/101\">",
"      Asavamongkolkul A, Eckardt JJ, Eilber FR, et al. Endoprosthetic reconstruction for malignant upper extremity tumors. Clin Orthop Relat Res 1999; :207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/102\">",
"      Safran MR, Kody MH, Namba RS, et al. 151 endoprosthetic reconstructions for patients with primary tumors involving bone. Contemp Orthop 1994; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/103\">",
"      Kawai A, Lin PP, Boland PJ, et al. Relationship between magnitude of resection, complication, and prosthetic survival after prosthetic knee reconstructions for distal femoral tumors. J Surg Oncol 1999; 70:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/104\">",
"      Wirganowicz PZ, Eckardt JJ, Dorey FJ, et al. Etiology and results of tumor endoprosthesis revision surgery in 64 patients. Clin Orthop Relat Res 1999; :64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/105\">",
"      Horowitz SM, Glasser DB, Lane JM, Healey JH. Prosthetic and extremity survivorship after limb salvage for sarcoma. How long do the reconstructions last? Clin Orthop Relat Res 1993; :280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/106\">",
"      Yasko AW, Reece GP, Gillis TA, Pollock RE. Limb-salvage strategies to optimize quality of life: the M.D. Anderson Cancer Center experience. CA Cancer J Clin 1997; 47:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/107\">",
"      Bickels J, Wittig JC, Kollender Y, et al. Distal femur resection with endoprosthetic reconstruction: a long-term followup study. Clin Orthop Relat Res 2002; :225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/108\">",
"      Eckardt JJ, Safran MR, Eilber FR, et al. Expandable endoprosthetic reconstruction of the skeletally immature after malignant bone tumor resection. Clin Orthop Relat Res 1993; :188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/109\">",
"      Schiller C, Windhager R, Fellinger EJ, et al. Extendable tumour endoprostheses for the leg in children. J Bone Joint Surg Br 1995; 77:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/110\">",
"      Eckardt JJ, Kabo JM, Kelley CM, et al. Expandable endoprosthesis reconstruction in skeletally immature patients with tumors. Clin Orthop Relat Res 2000; :51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/111\">",
"      Lewis MM. The use of an expandable and adjustable prosthesis in the treatment of childhood malignant bone tumors of the extremity. Cancer 1986; 57:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/112\">",
"      Wilkins RM, Soubeiran A. The Phenix expandable prosthesis: early American experience. Clin Orthop Relat Res 2001; :51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/113\">",
"      Donati D, Giacomini S, Gozzi E, Mercuri M. Proximal femur reconstruction by an allograft prosthesis composite. Clin Orthop Relat Res 2002; :192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/114\">",
"      Donati D, Capanna R, Casadei R, et al. Arthrodesis of the knee after tumor resection: a comparison between autografts and allografts. Chir Organi Mov 1995; 80:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/115\">",
"      Weiner SD, Scarborough M, Vander Griend RA. Resection arthrodesis of the knee with an intercalary allograft. J Bone Joint Surg Am 1996; 78:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/116\">",
"      Minami A, Kutsumi K, Takeda N, Kaneda K. Vascularized fibular graft for bone reconstruction of the extremities after tumor resection in limb-saving procedures. Microsurgery 1995; 16:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/117\">",
"      Shea KG, Coleman DA, Scott SM, et al. Microvascularized free fibular grafts for reconstruction of skeletal defects after tumor resection. J Pediatr Orthop 1997; 17:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/118\">",
"      Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106 Suppl:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/119\">",
"      Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003; 78:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/120\">",
"      Zaharia M, Caceres E, Valdivia S, et al. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/121\">",
"      Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/122\">",
"      Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group. Cancer 1988; 61:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/51/37690/abstract/123\">",
"      Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys 1988; 15:1233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7739 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37690=[""].join("\n");
var outline_f36_51_37690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tumor staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGICAL MANAGEMENT OF THE PRIMARY TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Types of resections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Resection margins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extremity lesions: limb-sparing procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Indications for amputation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Rotationplasty and the skeletally immature patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13145656\">",
"      - Upper extermity lesions involving the shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Non-extremity lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pelvic tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Spine tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECONSTRUCTION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Allografts and endoprostheses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Allografts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Metal endoprostheses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Expandable prostheses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Allograft-prosthetic composites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arthrodesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vascularized grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7739|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/47/2801\" title=\"diagnostic image 1\">",
"      Bone sarcoma imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/49/33552\" title=\"diagnostic image 2\">",
"      Periosteal osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/33/22036\" title=\"diagnostic image 3\">",
"      Pathologic fracture of a distal femur osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/3/27698\" title=\"diagnostic image 4\">",
"      MRI recurrent chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/49/15135\" title=\"diagnostic image 5\">",
"      Osteosarc osteoartic allograft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/43/39614\" title=\"diagnostic image 6\">",
"      Chondrosarc endoprosthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/35/22079\" title=\"diagnostic image 7\">",
"      Alloprosthesis reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7739|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/53/23391\" title=\"figure 1\">",
"      Components of a long bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/34/13864\" title=\"figure 2\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7739|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/27/17840\" title=\"picture 1\">",
"      Rotationplasty reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7739|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/43/26301\" title=\"table 1\">",
"      TNM staging bone tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/39/42620\" title=\"table 2\">",
"      Classify primary malignant bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/44/14029\" title=\"table 3\">",
"      Osteogenic sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/58/14251\" title=\"table 4\">",
"      Histol grading post preop chemo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5658?source=related_link\">",
"      Giant cell tumor of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/48/27394?source=related_link\">",
"      Patient information: Chondrosarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32599?source=related_link\">",
"      Primary lymphoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25338?source=related_link\">",
"      Radiation therapy for Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_51_37691="Lynch syndr CGC guidelines";
var content_f36_51_37691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lynch syndrome: Cancer Genetics Consortium management guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Intervention",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Recommendation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Men and women",
"      </td>",
"      <td class=\"subtitle2\">",
"       Women",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History and physical exam",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Every year beginning at age 21 with review of systems, education, and counseling regarding Lynch syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colonoscopy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Every 1-2 years beginning at age 20-25 years or 10 years younger than the youngest age at diagnosis in the family, whichever comes first.  For MSH6 families, begin at age 30.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colorectal resection",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Generally not recommended for primary prophylaxis, but if cancer diagnosed, subtotal colectomy is favored",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Transvaginal ultrasound",
"      </td>",
"      <td>",
"       Every year beginning at age 30-35 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hysterectomy with bilateral salpingo-oophorectomy",
"      </td>",
"      <td>",
"       Offer as option after childbearing complete",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urinalysis with cytology",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Every 1-2 years beginning at age 25-35 years",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Lindor, NM, Petersen, GM, Hadley, DW, et al. Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review. JAMA 2006; 296:1507.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37691=[""].join("\n");
var outline_f36_51_37691=null;
var title_f36_51_37692="Organophos carbamate structure";
var content_f36_51_37692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    General structures of organophosphate (left) and carbamate (right) agents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 124px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The variable R1 and R2 groups are composed of either methyl (CH3) or ethyl (CH3CH2) moieties. The leaving group is generally an oxime or an aromatic group. Organophosphorones are similar to organophosphates, but they lack a sulfur atom, and are instead bound to four oxygen molecules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37692=[""].join("\n");
var outline_f36_51_37692=null;
var title_f36_51_37693="Hormonal response to cirrhosis";
var content_f36_51_37693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hormonal response to cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cirrhosis of increasing severity - no ascites, ascites, and ascites plus renal failure (RF) due to hepatorenal syndrome - is associated with a progressive increase in plasma renin activity (ng/mL per hour) and in the plasma levels of norepinephrine (pg/mL), and antidiuretic hormone (pg/mL). This progressive rise in the secretion of hypovolemic hormones is associated with a vasodilatation-induced fall in mean arterial pressure (from 89 to 75 mmHg) and a reduction in the plasma sodium concentration (from 138 to 128 mEq/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Asbert M, Gines A, Gines P, et al. Gastroenterology 1993; 104:1485.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37693=[""].join("\n");
var outline_f36_51_37693=null;
var title_f36_51_37694="Contents: Medical consultation";
var content_f36_51_37694=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Medical consultation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Medical consultation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical consultation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/1/4120\">",
"           Evaluation of health-related quality of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/41/21145\">",
"           Medical consultation for electroconvulsive therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/48/41735\">",
"           Overview of the principles of medical consultation and perioperative medicine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/29/42456\">",
"           Surgical issues in HIV infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Perioperative care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/14/13544\">",
"           Noncardiac surgery in patients with aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/11/13495\">",
"           Noncardiac surgery in patients with mitral or aortic regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/22/19817\">",
"           Overview of anesthesia and anesthetic choices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/9/10394\">",
"           Perioperative care of the surgical patient with neurologic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/0/18440\">",
"           Perioperative heart failure in noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/63/29688\">",
"           Perioperative management of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/17/33046\">",
"           Perioperative management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/45/40666\">",
"           Perioperative medication management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postoperative care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39368\">",
"           Early cardiac complications of coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/25/35226\">",
"           Early noncardiac complications of coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/10/11434\">",
"           Overview of the management of postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/32/6664\">",
"           Perioperative nutritional support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/40/38537\">",
"           Postoperative complications among patients undergoing cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/46/19178\">",
"           Postoperative fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13113\">",
"           Strategies to reduce postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preoperative evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12858\">",
"           Assessing surgical risk in patients with liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/27/40378\">",
"           Carotid endarterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/8/1162\">",
"           Evaluation of preoperative pulmonary risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/14/13544\">",
"           Noncardiac surgery in patients with aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/11/13495\">",
"           Noncardiac surgery in patients with mitral or aortic regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39800\">",
"           Overview of preoperative evaluation and preparation for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/32/6664\">",
"           Perioperative nutritional support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/43/32439\">",
"           Preoperative assessment of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/2/15400\">",
"           Preoperative evaluation for lung resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/40/24201\">",
"           Preoperative management of patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/4/10314\">",
"           Preoperative medical evaluation of the healthy patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2D4678E6C8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_51_37694=[""].join("\n");
var outline_f36_51_37694=null;
var title_f36_51_37695="Criteria paranoid personality";
var content_f36_51_37695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52389%7EPC%2F62678%7EPC%2F75507%7EPC%2F80887%7EPC%2F50890%7EPC%2F63552%7EPC%2F59866%7EPC%2F81110%7EPC%2F72308%7EPSYCH%2F63127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52389%7EPC%2F62678%7EPC%2F75507%7EPC%2F80887%7EPC%2F50890%7EPC%2F63552%7EPC%2F59866%7EPC%2F81110%7EPC%2F72308%7EPSYCH%2F63127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for paranoid personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Suspects, without sufficient basis, that others are exploiting or deceiving him or her",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Is preoccupied with unjustified doubts about the loyalty or trustworthiness of friends or associates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Is reluctant to confide in others because of unwarranted fear that the information will be used maliciously against him or her",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Reads hidden demeaning or threatening meanings into benign remarks or events",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Persistently bears grudges, ie, unforgiving of insults, injuries, or slights",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Perceives attacks on his or her character or reputation that are not apparent to others and is quick to react angrily or counterattack",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Has recurrent suspicions, without justification, regarding fidelity of spouse or sexual partner",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for schizoid personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Neither desires nor enjoys close relationships, including being part of a family",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Almost always chooses solitary activities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Has little if any interest in having sexual experiences with another person",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Takes pleasure in few, if any, activities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Lacks close friends or confidants other than first-degree relatives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Appears indifferent to praise or criticism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Shows emotional coldness, detachment, or flattened affectivity",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for schizotypal personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Five or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Ideas of reference",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Odd beliefs or magical thinking, that influence behavior and are inconsistent with subcultural norms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Unusual perceptual experiences, including bodily illusions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Odd thinking and speech",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Suspiciousness or paranoid ideation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Inappropriate or constricted affect",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Behavior or appearance that is odd, eccentric, or peculiar",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Lack of close friends or confidants other than first-degree relatives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Excessive social anxiety that does not diminish with familiarity and tends to be associated with paranoid fears rather than negative judgments about self",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for antisocial personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A. There is a pervasive pattern of disregard for and violation of the rights of others indicated by three or more of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Failure to conform to social norms with respect to lawful behaviors as indicated by repeatedly performing acts that are grounds for arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Deceitfulness, as indicated by repeated lying, use of aliases, or conning others for personal profit or pleasure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Impulsivity or failure to plan ahead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Irritability and aggressiveness, as indicated by repeated physical fights or assaults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5. Reckless disregard for safety of self or others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        6. Consistent irresponsibility, as indicated by repeated failure to sustain consistent work behavior or honor financial obligations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        7. Lack of remorse, as indicated by being indifferent to, or rationalizing having hurt, mistreated, or stolen from another",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        B. The individual is at least 18 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        C. There is evidence of conduct disorder with onset before age 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        D. The occurrence of antisocial behavior is not exclusively during the course of schizophrenia or a manic episode",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for histrionic personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Five or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Is uncomfortable in situations in which he or she is not the center of attention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Interaction with others is often characterized by inappropriate sexually seductive or provocative behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Displays rapidly shifting and shallow expression of emotion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Consistently uses physical appearance to draw attention to self",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Style of speech that is excessively impressionistic and lacking in detail",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Shows self-dramatization, theatricality, and exaggerated expression of emotion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Is suggestible, ie, easily influenced by others or circumstances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Considers relationships to be more intimate than they actually are",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for narcissistic personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Five or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Has a grandiose sense of self-importance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Is preoccupied with fantasies of unlimited success, power, brilliance, beauty, or ideal love",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Believes he or she is \"special\" and unique and can only be understood by or should associate with other special or high-status people (or institutions)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Requires excessive admiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Has a sense of entitlement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Is interpersonally exploitative, ie, takes advantage of others to achieve his or her own ends",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Lacks empathy: unwilling to recognize or identify with the feelings and needs of others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Is often envious of others or believes that others are envious of him or her",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Shows arrogant, haughty behaviors or attitudes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for avoidant personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of the following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Avoids occupational activities that involve significant interpersonal contact because of fears of criticism, disapproval, or rejection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Is unwilling to get involved with people unless certain of being liked",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Shows restraint within intimate relationships because of the fear of being shamed or ridiculed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Is preoccupied with being criticized or rejected in social situations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Is inhibited in new interpersonal situations because of feelings of inadequacy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Views self as socially inept, personally unappealing, or inferior to others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Is unusually reluctant to take personal risks or to engage in any new activities because they may prove embarrassing",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for dependent personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Five or more of the following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Has difficulty making everyday decisions without an excessive amount of advice and reassurance from others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Needs others to assume responsibility for most major areas of his or her life",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Has difficulty expressing disagreement with others because of fear of loss of support or approval",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Has difficulty initiating projects or doing things on his or her own (because of a lack of self-confidence in judgment or abilities rather than a lack of motivation or energy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Goes to excessive lengths to obtain nurturance and support from others, to the point of volunteering to do things that are unpleasant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Feels uncomfortable or helpless when alone because of exaggerated fears of being unable to care for himself or herself",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Urgently seeks another relationship as a source of care and support when a close relationship ends",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Is unrealistically preoccupied with fears of being left to take care of himself or herself",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for obsessive-compulsive personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of the following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Is preoccupied with details, rules, lists, order, organization, or schedules to the extent that the major point of the activity is lost",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Shows perfectionism that interferes with task completion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Is excessively devoted to work and productivity to the exclusion of leisure activities and friendships",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Is overconscientious, scrupulous, and inflexible about matters of morality, ethics, or values (not accounted for by cultural or religious identification)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Is unable to discard worn-out or worthless objects even when they have no sentimental value",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Is reluctant to delegate tasks or to work with others unless they submit to exactly his or her way of doing things",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Adopts a miserly spending style toward both self and others; money is viewed as something to be hoarded for future catastrophes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Shows rigidity and stubbornness",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for borderline personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1.",
"        </strong>",
"        Frantic efforts to avoid real or imagined abandonment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2.",
"        </strong>",
"        A pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3.",
"        </strong>",
"        Identity disturbance: markedly and persistently unstable self-image or sense of self",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         4.",
"        </strong>",
"        Impulsivity in at least two areas that are potentially self-damaging (eg, spending, sex, substance abuse, reckless driving, binge eating)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         5.",
"        </strong>",
"        Recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         6.",
"        </strong>",
"        Affective instability/marked reactivity of mood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         7.",
"        </strong>",
"        Chronic feelings of emptiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         8.",
"        </strong>",
"        Inappropriate, intense anger or difficulty controlling anger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         9.",
"        </strong>",
"        Transient, stress-related paranoid ideation or severe dissociative symptoms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright &copy; 2000 American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_51_37695=[""].join("\n");
var outline_f36_51_37695=null;
